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ABSTRACT
DEVELOPMENT AND APPLICATIONS OF IN-VITRO AND IN-SILICO MODELS
OF THE CARDIOVASCULAR SYSTEM TO STUDY THE EFFECTS OF
MECHANICAL CIRCULATORY SUPPORT
Moustafa H. Meki
November 15, 2021
Cardiovascular diseases (CVDs) are the leading cause of mortality globally. With
ongoing interest in CVDs treatment, preclinical models for drug/therapeutic development
that allow for fast iterative research are needed. Owing to the inherent complexity of the
cardiovascular system, current in-vitro models of the cardiovascular system fail to
replicate many of the physiological aspects of the cardiovascular system. In this
dissertation, the main concern is with heart failure (HF). In advanced HF, patients may
receive Left Ventricular Assist Devices (LVADs) as a bridge to transplant or destination
therapy. However, LVADs have many limitations, including inability to adapt to varying
tissue demand conditions, risk of ventricular suction, and diminished arterial pulsatility.
To address these issues, this dissertation aims to use and develop computer, cellular, and
tissue models of the cardiovascular system. 1) Use an in-silico model of the
cardiovascular system to develop a novel control algorithm for LVADs. The control
system was rigorously tested and showed adequate perfusion during rest and exercise,
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protect against ventricular suction under reduced heart preload, and augment arterial
pulsatility through pulse modulation without requiring sensor implantation or modelbased estimations.
2) While pulsatility augmentation was feasible through the developed control algorithm,
the pulse waveform that could normalize the vascular phenotype is unknown. To address
this, an endothelial cell-smooth muscle cell microfluidic coculture model was developed
to recreate the physiological mechanical stimulants in the vascular wall. The results
demonstrated different effects of pulsatile shear stress and stretch on endothelial cells and
may indicate that a pulse pressure of at least 30 mmHg is needed to maintain normal
endothelial morphology.
3) In order to study the effects of mechanical unloading on the native ventricle, a novel
cardiac tissue culture model (CTCM) was developed. CTCM provided physiological
electromechanical and humoral stimulation with 25% preload stretch and thyroid and
glucocorticoid treatment maintained the cardiac phenotype for 12 days. The device was
thoroughly characterized and tested. Results demonstrated improved viability, energy
utilization, fibrotic remodeling, and structural integrity compared to available culture
systems. The system was also used to reproduce ventricular volume-overload and the
results demonstrated hypertrophic and fibrotic remodeling, typical of volume-overload
pathology.
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CHAPTER 1: INTRODUCTION1
1
The cardiovascular system is composed of three main components: 1) the heart, 2) the
blood vessels, and 3) the blood. Blood is circulated by the heart through the lungs and
carries dissolved oxygen and nutrients through the arterial circulation to the whole body
via a vast network of micro capillary circulation. At the tissue level, oxygen and nutrients
are delivered to the tissue, while carbon dioxide and metabolic waste are removed and
circulated d back to the lung through the venous circulation.

1.1 Heart Function and Cellular Organization
Gross Anatomy of the Heart
The heart serves as a pump to circulate blood throughout the body and provide
oxygenated, nutrient-rich blood to the tissue. A schematic view of the heart structure is
shown in Figure 1-1-A. Anatomically, the heart is composed of two pumps: a right heart
that pumps blood through the lungs, and a left heart that pumps blood through the
peripheral organs. Each of the two pumps is composed an atrium and a ventricle. The
right atrium receives deoxygenated blood from the venous circulation through the vena
cavae and passes it to the right ventricle through the tricuspid valve. The right ventricle
pumps the blood across the pulmonary valve to the pulmonary arteries and into the
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pulmonary circulation where gas exchange takes place. Oxygenated blood is drawn into
the left atrium through pulmonary veins and passed through the mitral valve to the left
ventricle. The left ventricle pumps oxygen-rich blood to the systemic circulation to all the
end organs. As shown in Figure 1-1-A, the right ventricular wall is thinner than the left
ventricular wall. This is because the hydraulic vascular resistance of the pulmonary
circulation is folds less than the systemic circulation, and therefore cardiomyocyte size
(active contractile cells of the myocardium) is on average less than the right ventricle
than the left ventricle. [2]
Cellular Organization of the heart
The heart is composed of three types of cardiac muscles: atrial muscle, ventricular
muscle, and electrical excitatory and conductive muscle fibers. Like skeletal muscles, the
myocardium is straited and contracts using myofibrils containing actin and myosin
filaments that will slide over each other in response to electrical stimulation [3]. Unlike
skeletal muscles, however, cardiac muscles have intercalated disks that separate each
cardiomyocyte from one another. The intercalated disks are fusion points for the cell
membrane to allow for ion diffusion from one cell to the other. At each intercalated disk,
the cell membranes fuse. This allows action potentials to freely travel from one
cardiomyocyte to the other in syncytium through a latticework of interconnections as
show in Figure 1-1-B. Therefore, functionally, ions can move easily in the intracellular
fluid along the longitudinal axis of the cardiac muscle fibers and from one cardiomyocyte
to the next. That being said, there are two syncytia in the heart: 1) the atrial syncytium
which includes the left and right atrial walls, and 2) the ventricular syncytium which
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includes the left and right ventricular walls. The two syncytia can only communicate
through a conductive path of specialized cells, A-V bundle.
Structurally, the ventricular wall is composed of three layers, as shown in Figure 1-1C: 1) A fibrous outer pericardium, 2) Contractile myocardium and 3) inner layer
endocardium. Endocardium consists of loose connective tissue and epithelium [2, 4] and
is similar in structure to the endothelium. The majority of the myocardium is composed
of cardiomyocyte that are responsible for the heart contraction. The epicardium is
composed of fatty and connective tissue that helps aid the heart structurally as well as
produce a lubricating fluid into the pericardial cavity. [2]

Figure 1-1 A- Gross anatomy of the heart: The heart is composed of 4 chambers. The left
ventricle pumps oxygenated blood from the lungs to various organs. The right ventricle
pumps blood from the venous circulation to the lungs, B- representative image of
myocardial tissue, showing the latticework structure of cardiomyocytes with intercalated
disks as darker lines, C- The ventricular wall is composed of three layers. The middle
myocardial layer contains the contractile cardiomyocytes that will actively contract and
pump blood in the body.
3

The Cardiac Cycle
Each cycle is initiated by the generation of an action potential from the sinus node.
The sinus node is located in the upper portion of the right atrium. The action potential
travels through the atria and to the A-V bundle into the ventricles after a brief 100 𝑚𝑠
delay. This delay allows the atrial contraction to occur briefly before the ventricular
contraction which permits enough time for the atrium to act as a priming pump to fill the
ventricles. As shown in Figure 1-2, the heart cycle consists of a ventricular relaxation
period where the ventricles are relaxing and being filled with blood while the atria are
contracting to boost the blood flow into the ventricle (ventricular diastole). This period is
followed by a contraction phase where the right and left ventricles contract to eject blood
through the pulmonary and aortic valves respectively and the atria are relaxing
(ventricular systole). Ventricular contraction can be divided into two portions: an
isovolumetric contraction phase where the ventricular pressure rises rapidly with no
change in volume, and an active contraction phase where the pulmonary and aortic valves
open, and blood is ejected. Similarly, during ventricular relaxation there is a duration
where the ventricular pressure is falls rapidly with no change in volume, followed by a
period where the mitral and tricuspid valves open, and blood fills the ventricles. While
the cardiac cycle can change significantly during different physical conditions, the
systolic duration accounts for ~40% of the cardiac cycle while the diastolic duration
represents ~60% . [5] The pulmonary and aortic valves are differential pressure operated.
This means that when the aortic/ pulmonary artery pressure is lower than the ventricular

4

pressure, the valves open and will remain closed otherwise. The normal arterial pressure
peak is ~120 mmHg, and the lowest pressure during diastole is ~80 mmHg.

Figure 1-2 Wiggers diagram showing the ventricular volume, ventricular, atrial, and
arterial pressures as function of time. Adapted from Wikimedia Commons: Wiggers
Diagram.svg.
Hemodynamic loading is very important in the regulation of cardiac morphogenesis.
The heart experiences two types of loads: preload and afterload. Preload refers to the
initial stretching of the myocardium prior to contraction. Therefore, preload is related to
the sarcomere length. The degree of stretch that is experienced by the tissue depends on
the amount of blood that is being returned to the heart from the venous system, known as
venous return. [6] When venous return to the heart increases, the pressure at the end of
diastole also increases and the sarcomere is stretched which is increases preload. In
contrast, a decrease in blood volume due to blood loss leads to decreased venous return
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and decreased preload. Heart stroke volume and cardiac output are closely related to
preload through the Frank-Starling mechanism which states that an increase in preload
will lead to an increased stroke volume and a decrease in preload will lead to a decrease
in stroke volume. [6, 7] Afterload is thought of as the load that the heart has to overcome
to eject blood. Thus, it can also be thought of in terms of the ventricular wall stress.
Afterload is ultimately dependent on the aortic pressure. In a simplified spherical
representation of the ventricle (Figure 1-3), Wall stress can be expressed as

𝜎𝜃 =

𝑝𝑖 𝑎2 − 𝑝𝑜 𝑏 2
𝑏 2 − 𝑎2

(1)

Where 𝜎𝜃 is the average wall stress, 𝑝𝑖 is the ventricular pressure, 𝑝𝑜 is the pericardial
pressure, 𝑎, and 𝑏 are the inner and outer ventricular diameters, respectively. From
equitation 1 it is easy to see that the maximum wall stress happens when 𝑝𝑖 is at a
maximum. It should also be noted that any enlargement in the heart that increases the
heart radius will increase myocardial wall stress to the second power.
Under increased afterload, the myocardium will respond by increasing contractile
protein as well as RNA and DNA synthesis. [8] Indeed, the mechanical cues in the native
heart play an essential role in steering physiological or pathological remodeling such as
dilated or hypertrophic cardiomyopathy. [9] In-vitro studies using cardiomyocytes in
culture have shown the importance of mechanical stimuli to maintain and promote
phenotypic characteristic of mature cardiomyocytes. [10, 11] During heart development,
the heart is very responsive to mechanical cues, and it will not develop properly if blood
flow is absent. Hence, any alterations to the normal hemodynamics stresses experienced

6

by the developing tissue will result in cardiac malformations and congenital heart defects.
[12, 13]

Figure 1-3 Simplified model of the ventricular wall as a thick-walled sphere. Balance of
pressure forces shows the dependence of afterload and wall stress on ventricular diameter
and pressure.

1.2 Vascular Function and Cellular Organization
Anatomy of the Vasculature
The vasculature consists of arteries, arterioles, capillaries, venules, and veins. Any
cell in the body is on average 40 µ𝑚 away from a capillary and all tissue is fully infused
with an intricate network of capillaries. Typically, the human body contains ~5 liters of
blood .[14] The vascular system can be divided into two parts: the pulmonary
circulation and the systemic circulation. The pulmonary circulation loops from the right
heart, through the lungs, and back into the left heart. The systemic circulation loops from
the left heart, through the entire body and back to the right heart. Generally, for both
circulations blood is supplied by the heart to large arteries which branch into smaller
arteries and end with arterioles and capillaries. The capillary bed gradually joins together
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to form larger veins to return blood to the heart. For humans, the aorta which is the
largest blood vessel varies between 2.5 cm to 3.4 cm in diameter. [15] The vascular
system must fulfill three primary functions [16]: 1) Enable efficient mass transfer to the
tissue. This function is readily achieved by the capillaries which are a monolayer of
endothelial cells (ECs) and have an enormous surface area ~ 300 𝑚2 , 2) regulate blood
distribution in response to metabolic needs of the perfused tissue. The majority of the
hydraulic resistance of the vasculature is generated through the arterioles and capillaries.
Smooth muscles that surround the inner endothelial wall of the blood vessels will relax
and contract in response to neural or humoral stimuli. Thus, blood flow can be directed to
areas where it is needed and away from where it is not. 3) Maintain a blood reservoir.
The veins contain almost two thirds of the blood content of an adult human. This is
important in case of blood loss, so the body does not immediately go into hemorrhagic
shock.
Arterial Wall Structure
The wall of the artery consists of three layers, as shown in Figure 1-4-A. The
innermost layer is called tunica intima which consists of a monolayer of endothelial cells
and a basal membrane. The basal membrane contains type IV collagen, fibronectin, and
laminin. Tunica media consists of Smooth Muscle cells (SMCs) and is separated from the
intima by thin elastin layer. The outermost layer is known as tunica adventitia and is
composed of loose connective tissue containing type I collagen, fibroblasts, and a lower
amount of elastin fibers. The vascular smooth muscles are circumferentially oriented and
play an important role in regulating the vascular tone and arterial stiffness.
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Figure 1-4 A Typical anatomical structure of the artery. The figure shows three layers:
tunica intima, tunica media, and tunica adventitia, source: Encyclopædia Britannica , BInner endothelial wall is in contact with the blood flow and is the first responder to the
mechanical cues within the vessel lumen including, hydraulic pressure, shear stress ,and
stretch, adapted from [17].
The endothelial layer on the inside is in constant contact with the inner blood flow
and will thus react to the mechanical forces generated by the pulsatile flow through the
vessel lumen. Endothelial cells can communicate these stimuli to promote or repress
vasodilatation, inflammation, tissue remodeling, proliferation, apoptosis, or cell
migration, (e.g., [18-20]). This is graphically represented in as shown in Figure 1-4-B.
However, the components of the vascular wall vary drastically along the vascular tree.
While the large arteries have a thick media with obvious multi smooth muscle layers, the
veins have a much thinner media, while the capillaries are only composed of an
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endothelial monolayer. This can be understood by noting at the mean blood pressure
along the vascular tree. As shown in Figure 1-5, The mean pressure is ~ 100mmHg at
the aorta with a 40mmHg pulse pressure ( 𝑃𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 − 𝑃𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 ). However, as the blood
flows through the systemic circulation, the pulse pressure is greatly reduced (almost 0
mmHg at the capillaries) and the mean pressure is also reduced, especially across the
arterioles. The high blood pressure in the large arteries require the vessel wall to be
structurally stronger, with a higher expression of elastin fibers and smooth muscle layer
thickness compared to small arteries and arterioles.

Figure 1-5 Changes in blood pressure and pulsatility along the vascular tree. The mean
pressure and pulse pressure are the highest at the aorta and values drop as blood moves
along the branches, adapted from [2]
Regulation and function of ECs and SMCs in the vascular wall
ECs form a continuous barrier between blood and tissue. In addition to allowing diffusion
of biological substrates, ECs work as a non-thrombogenic surface, and can regulate
leukocyte entry into tissue. Healthy endothelium secretes tissue factor pathway inhibitor
and expresses anticoagulant proteins on their cell membrane such as heparin sulfate and
10

ADPase, thereby inhibit platelet deposition and blood clots formation. [21] Importantly,
ECs have been shown to respond to shear stresses induced by blood flow. Physiological
levels of shear stresses cause ECs to align in flow direction, inhibit angiogenesis, and
reduce inflammatory response markers. [22] In contrast, low levels of shear stress have
been shown to induce vasoconstriction, cellular misalignment, and expression of
proinflammatory and oxidative stress genes. [22, 23]
SMCs are in a quiescent state in the adult blood vessels and express high level of
contractile protein to regulate the vascular tone. However, SMCs can shift to a
proliferative phenotype in response to injury or in culture, where they release growth
factors that stimulation of SMC migration, growth, and ECM synthesis. [24] SMCs have
been shown to respond to cyclic stretch that is associated with pulsatile flow domains.
[25]SMCs regulate the diameter of arterioles and small arteries in response to blood
pressure changes, and any increase in blood pressure above normal level will stretch
SMCs and induce the contraction of SMCs to maintain the vessel diameter within a
narrow range. This response is largely communicated through the stretch signal and ECs
secretion in response to shear stress changes[26]

1.3 Modeling of the cardiovascular system
Various models of the cardiovascular system have been developed at different degrees of
complexities. The choice of the appropriate model is solely up to the research question at
hand. These models can provide critical guidance in preclinical and translational research
and may be limited to certain parts of the cardiovascular system (e.g, heart tissue or
cardiomyocyte) or may model the entirety of the cardiovascular system as in
hemodynamical modeling. Such models can include animal, cellular, tissue, and
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computer models. Herein, hemodynamical modeling, vascular modelling, and heart
modeling are reviewed.
Hemodynamical Modeling of the Cardiovascular System
In order to better understand the cardiovascular system, the use of mathematical
models and numerical simulations has proven to be a powerful tool in understanding the
mechanisms that mediate its function in both normal and pathological conditions. Such
models vary drastically in complexity and thus the selection of the appropriate
complexity depends on the aims and the accuracy necessary for the research study. [27]
Linearized mathematical models of the Cardiovascular system can be broadly classified
based on dimensionality into lumped parameter (zero dimensional, 0D), or distributed
parameter (1D, 2D, and 3D). Lumped parameter models assume a uniform distribution of
pressure, flow, and volume within each block at any time. Distributed parameters models,
however, can detect the variations of these parameters in space, as illustrated in Figure
1-6-A. Lumped parameter models are usually based on the Windkessel model [28] which

is most widely used. Here, the vascular system is lumped in to single or multiple
compartments, each of which is comprised of two elements: a resistance and a
compliance element. [29, 30] Other elements can be added to account for inertance or
characteristic impedance, which gives rise to the three and four element Windkessel
model [28, 30]. Windkessel models are attractive because of their low computational
costs and ability to reproduce pulse wave propagation in time domain. [31] In distributed
models, however, the pulse waveform depends on both time and space. Additionally, in
multicompartment model heart valves can be incorporated to add discontinuities to the
flow and simulate transient effects all while still using numerical solutions of ordinary
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differential equations. An example of this is shown in Figure 1-6-B. [32] 1D models use
simplified Navier-Stokes equation to recreate the flow pressure and velocity along the
vascular tree. [33] 3D models are usually used to simulate local flow regimes in a limited
area of interest. A 3D model of appropriate accuracy can capture the interaction between
the flow with the vessel wall using Fluid-Structure-Interaction. Indeed, such simulations
are of high complexities and cannot be used to simulate gross effects within the arterial
tree and are thus limited to local hemodynamics in an area of interest.

Figure 1-6, A- Comparison between lumped parameter models and distributed models. A
Windkessel lumped parameter model represents the vascular system as two elements with
a compliance and a resistance. Higher order distributed models can provide spatial
description of the pressure and flow velocity, but are computationally expensive, BAdapted from [34], example of a sophisticated multicompartment lumped parameter model
where different elements of the pulmonary and systemic circulation are modeled.
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In-vitro modeling of vascular physiology
Over the past decade, cell culture technology and microfluidics have advanced
significantly and have thus enabled the development of culture systems that can more
accurately represent the native in-vivo physiology. [35] In cardiovascular research, such
systems are highly desirable due to the innate complexity of cardiovascular diseases and
the subsequent difficulty in studying drugs that target both key risk factors and the
manifestations of cardiovascular diseases.[35] Several cellular models have been
developed to model the vascular physiology and pathophysiology. These models have
mainly incorporated endothelial cells (ECs) and to a lower extent smooth muscle cell
(SMCs), being the major cellular components of arteries and veins.
1.3.2.1 Advancements in vascular modeling
Recent advancements in microfluidics and organ-on-a-chip research have brought 3-D
cultures of primary human cells to create biomimetic models of organs and tissue. Such
models incorporate many of the physiological phenomenon of the native organ and
tissue. Most microfluidic devices for vascular modeling are fabricated using polydimethylsiloxane (PDMS) to create structures and channels using soft lithography from a
mold or template. The small dimensions (<1 mm) of these microchannels ensure a
laminar flow regime throughout the model. Fluid mechanics of laminar, low Reynold’s
number (𝑅𝑒) flows are well defined and understood which allows for precisely modulated
flow environments as well as high resolution complex geometries. Moreover, the small
footprint of microfluidic devices allows for high throughput experimentation.
Microfluidic devices have been used to study the hemodynamics of the large arteries. [36,
37] More involved systems were developed to study the microcirculation and was able to
14

reproduce red blood cell (RBC) deformation at the capillary level. [38]Other groups have
also developed microchannel systems to study the effects of shear stress on the
endothelial phenotype. [39-41]
1.3.2.2 Current state of EC-SMC co-cultures to model vascular wall
As previously discussed, the interaction between ECs and SMCs in-vivo are vast and
several co-culture models of ECs and SMCs have been used to model the normal [42]
and diseased vessel wall. [43] ECs and SMCs can be co-cultured in 3 variations, as
shown in Figure 1-7 [35] 1) ECs and SMCs on opposite sides of a membrane[44-46], 2)
ECs are cultured on gels with embedded SMCs (e.g., collagen containing SMCs) [47,
48], and 3) ECs are directly cultured above SMCs [49, 50]
The advantage of having a porous membrane to separate the two cell types is to
permit the easy separation of the two cell lines for further analysis and limit overgrowth.
However, the introduction of a stiff synthetic substrate, much stiffer than in-vivo, can also
greatly affect the SMCs proliferation and upregulate VEGF,PDGF and TGF-B1
expression in culture. [[[40,54]]] Indeed, the coculture of ECs and SMCs together in the
presence of a porous membrane promoted a more physiological, elongated EC phenotype
in contrast to the more polygonal ECs morphology seen with ECs alone in in-vitro
cultures. [47] Additionally, the presence of SMCs promoted EC expression of TF, VEGF,
and adhesion molecules [44, 51, 52]
The separation ECs and SMCs when they are directly cocultured is laborious and
can be achieved using coated magnetic beads, specific to one of the cell lines (usually
ECs) [53]
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The closeness of ECs and SMCs in direct co-culture increases contact and
decreases the diffusion distance. This has been shown to promote physiological ECM
synthesis and protein expression. [54] In the absence of SMCs, ECs will rapidly migrate
into collagen and fibrin gels. However, the presence of SMCs inhibits EC proliferation,
allowing such cultures to be stable for longer. The use of collagen gels containing SMCs
instead of directly culturing layers of ECs and SMCs together has been used to better
mimic the in-vivo intima. This is needed because although ECs can produce several basal
proteins such as collagen II and IV, there has not been much success in creating a wellformed intima in-vitro. [55, 56] Nonetheless, direct cocultures methods can best mimic
the physiological structure of the vessel wall and use fewer cells than other types of
culture.

Figure 1-7 Schematic representation of different variations of EC-SMC cocultures
arrangements from literature. (A) ECs and SMCs are cultured on both sides of a porous
membrane to facilitate cell separation. B) ECs are cultured on top of SMCs embedded in
a collagen matrix, C) ECs are directly cultured on top of SMCs similar to physiology, and
D) A mixed culture of ECs and SMCs. Figure adapted from [35]
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In-vitro cellular modeling of cardiac physiology
Before clinical studies, there is a need for reliable experimental systems that can
accurately replicate the human heart's physiological environment. Such systems should
model altered mechanical loading, heart rate, and electrophysiological properties. The
most prevalently used cardiac physiology screening platform are animal models and
those have limited reliability in mirroring the effects of drugs in human hearts [57, 58].
Additionally, the use of animal models to create a pharmacokinetic profile of drugs is
relatively expensive at the early development stage since large amounts of the drugs are
used [59]. Ultimately, the ideal cardiac model is one that demonstrates high sensitivity
and specificity towards various therapeutic and pharmacological interventions while
accurately replicating the physiology and pathophysiology of the human heart [60].
1.3.3.1 In-vitro modeling of the human myocardium
In-vitro systems using a controlled culture environment have the unique
advantage of quantitatively characterizing drug-related changes at the cellular level with
relatively lower cost. These systems' success depends on how much clinically relevant
information can be detected through them. This includes contractility measurements,
protein expression (e.g., gap junction proteins and contractile proteins), accurate
transcriptional profile, calcium homeostasis, and electrophysiology. Additionally, the
applicability of the system to human cells is of paramount importance. Guth et al. [59]
summarized the most relevant features and considerations for in-vivo drug testing
platforms. Nonetheless, 28% of drug withdrawals are owed to unanticipated
cardiotoxicity [61]. This only shows that current cardiac models are unsuitable for
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preclinical drug testing and development. To this end, there have been many efforts to
develop reliable preclinical models to mimic the human heart tissue.
Thin heart slices are a relatively new technology that has emerged in recent years
and has shown promise in providing a system of adequate complexity and viability to
allow for drug screening [62]. They retain the adult phenotype, including the adult heart's
multicellularity and extracellular structure, and have been produced from human cardiac
tissue and large mammals.
While each in-vitro model has its advantages, each model has shortcomings in
modeling the physiology/pathophysiology of an adult human heart. This is owed to the
heart tissue's complex environment where multiple cell types interact under chronic
neurohormonal stimulation to maintain normal heart homeostasis. It is thus
understandable that there are many challenges in reproducing this complexity in culture.
Historically, there are a few in-vitro models that have been instrumental in our
cellular level understanding of the cardiac system: 1) Isolated adult cardiomyocytes, 2)
human-induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs), and 3)
arterially perfused ventricular wedge preparations. We describe each of these systems
herein and introduce their advantages and disadvantages compared to heart slice
preparations.
1.3.3.2 Animal/Human isolated adult cardiomyocyte
One of the oldest and simplest cardiac models is the use of isolated human
cardiomyocytes. The first isolated cardiomyocyte from adult hearts failed to last for a
reasonable time in culture and lacked proper phenotypic characteristics [63-65].
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Successful isolation and culture of adult cardiomyocytes were performed first by Powell
and Twist in 1976 [66]. Since then, cultured adult isolated cardiomyocytes have been
primarily used to study cardiac electrophysiology [67, 68], response to sepsis [69], Ca+2
dynamics [70, 71], gene transfer [72] , and contractile function [73, 74]. Indeed, the
simplistic unicellularity of isolated primary cardiomyocytes provides experimental
strength by avoiding extraneous influences from other tissue components [75]. Moreover,
when cultured adhering to a coated plastic surface, they will retain many adult
cardiomyocyte phenotype characteristics including cell-cell coupling, T-tubule
organization, and rod-shaped morphology [76]. While having been instrumental to
cellular level research, adult isolated cardiomyocytes' appropriateness for predicting
cardiotoxicity and macrolevel response to drugs and therapies is restricted. Although
isolated cardiomyocytes can survive for weeks, the single cell-type culture will rapidly
dedifferentiate and lose function within 48 hours of culture [77]. Additionally, the low
cell yield with currently used enzymatic isolation protocols and cellular damage limit
their use in high throughput screening [78-80]. Adult isolated primary cardiomyocytes
may be unsuitable for long-term drug screening due to their limited life span in culture
and its nature of replicating only a single cell type. Nevertheless, recent efforts have
focused on improving isolation protocols to improve cell yield and lowered the damage
to the cardiac tissue [81]. Notably, Callaghan et al. [82] have shown that Geltrex and
blebbistatin using adult mouse cardiomyocytes enhanced survival in culture with
maintained cellular function. However, the inhibition of cardiomyocyte contraction using
blebbistatin may limit the model’s use to study cardiomyocyte contractility.
1.3.3.3 Human-Induced Pluripotent Stem Cell-derived Cardiomyocytes
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Human-induced pluripotent stem cells (hiPSC) reprogramming was first
demonstrated in 2007 [83], and hiPSC derived cardiomyocytes (hiPSC-CMs) have since
been extensively used to determine drug cardiotoxicity, arrhythmogenicity [84-86], and
cardiac disease modeling [87, 88] due to the relative simplicity of hiPSC-CMs generation
and culture process [89]. However, it is well known that hiPSC-CMs are structurally and
functionally similar to fetal cardiomyocytes due to their lack of cell-cell coupling, underdeveloped sarcoplasmic reticulum, and no T-tubules; hence slow excitation-contraction
coupling [89].
With these apparent limitations in mind, several efforts have been conducted to
promote their maturation, discussed in detail in Ahmed et al. review [90]. These studies
aim to mimic certain cardiac milieu stimuli using integrated heart-on-chip systems to
include extracellular matrix [91], 3-D structure [92, 93], electrical [94, 95], and electromechanical stimulation [96-98]. Notably, Kroll et al., [99] developed a force stretch
system that can apply synchronized mechanical stress and electrical stimulation on
hiPSC-CMs cultured on a flexible PDMS membrane. They have shown enhanced Ncadherin signal, stress fiber formation, sarcomere shortening, and contractile protein
expression with hiPSC-CMs conditioning, indicating a trend towards maturation, as
thoroughly reviewed here. [100-103] These advancements allow the hiPS-CMs to
become the most widely used platform for drug screening due to their stability in culture
for a long time and their physiological resemblance to the human heart.
1.3.3.4 Animal-derived arterially perfused left ventricular wedge preparations
Arterially perfused left ventricular wedges were developed by Yan and
Antzelevitch in 1996 [104, 105] using canine hearts. Since then, ventricular wedge
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preparations have been expanded to other animal models, including humans, and have
been extensively used in studying heart electrophysiology, conduction velocity, and the
development of arrhythmia [106-109]. The advantage of this model is producing 3dimensional tissue-level insight into cardiac physiology and pathophysiology.
However, where ventricular wedges fall short is the relatively low throughput of
the preparation due to the coronary system's complexity and, therefore, low sample yield
per heart, [110] limiting their use in drug testing. Furthermore, the preparations can only
remain viable for a few hours in perfusion before suffering a similar fate to isolated
cardiomyocytes [111] restricting their use in subacute and chronic studies. Such a system
as a drug screening platform would be challenging due to the short life in culture and the
low throughput.
1.3.3.5 Animal/human-derived heart slices to model cardiac physiology
The first thin (<400 μm) heart slices were developed in 1992 [112] in the advent
of tissue slicing technology with relatively high precision and reproducible slice
thicknesses. In this study, rat ventricular heart slices were cultured for 24 hours with
maintained viability and metabolism [112]. The key feature was the use of continuously
oxygenated media while rotating the culture within a cylinder. Brandenburger et al.,
[113] 10 years later developed a more simplistic approach to overcome the inadequacies
with isolated cardiomyocytes and ventricular wedge preparations by using a transwell to
allow for a liquid-air interface.
Thin heart tissue slices (300 μm) have since been shown to achieve high viability,
retain typical tissue architecture, contractility, calcium handling, and conduction velocity
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for 24 hours [111, 114]. Additionally, heart slices maintain a 3-dimensional structure
with the multi cell-type environment and the presence of extracellular matrix (ECM).
This allows for other cellular components in the heart slices and ECM to interact with the
cardiomyocytes through direct cellular contact or paracrine secretion, which is essential
to maintain a mature cardiomyocyte phenotype [115, 116]. It is important to note that
heart slices and ventricular wedge preparations are different. Thin heart slices could
remain viable and functional in culture for 24 hours, do not require external perfusion,
and obtain oxygen and nutrients directly from culture media. These unique advantages
make them adequate for medium to high throughput systems for drug discovery.
Since their inception, heart slices have been prepared from several animals as well
as human hearts. Detailed protocols for preparing heart slices have been described here
[113, 114, 117, 118]. While multiple factors control the maturation and regulation of the
adult cardiac phenotype, the structural fidelity of heart slices provides cell-cell
interactions, transmembrane regulation and maintains standard tissue stiffness. These
heart slices' thinness simplifies nutrient and oxygen diffusion through the tissue and
provides a “pseudo” 3-dimensional model that can allow for multiplexed cellular-level
studies. Pseudo-3-dimensional model refers to the large surface area to thickness ratio of
the heart tissue slices, which does not compromise the tissue's 3-D structure while
maintaining proper substrate exchange.
1.3.3.6 Recent advancements in heart slices
Early transwell culture of cardiac slices by Brandenburger et al. maintained
viability, ß-adrenergic response, and many electrophysiological properties for 28 days
[113]. However, the prolonged culture of heart slices in transwell systems produced an
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observable loss in the tissue's structural and functional integrity after 24 hours in culture
shown by a >90% drop in contractility. The observed tissue remodeling reaffirmed this
with a dedifferentiated cardiomyocyte phenotype and a significant reduction in mRNA
expression of MLC2 and α-actin [113]. Subsequent efforts used the same transwell
system to culture heart slices 24 hours using human and other vertebrate hearts [111,
114]. Indeed, the heterogeneous heart slice preparation incorporates many organotypic
characteristics of the myocardium, but they will undergo dedifferentiation due to the nonphysiological environment in culture [112, 113, 119].
The native heart experiences several hemodynamic and neurohormonal factors
which precisely compose its ideal environment for functional integrity [9]. Disruption of
this balance in culture will ultimately promote some level of adaptive remodeling within
the heart. This highlights the importance of incorporating biomimetic stimulants to
maintain cardiac phenotype properly. But given the cardiovascular system's complexity,
it is difficult to define all the cardiac milieu constituents responsible for this balance.
In 2019, several efforts were taken to prolong the functional viability of the heart
slices in culture. The most relevant factors addressed in these efforts are biophysical
stimulation through electrical pacing, mechanical loading (preload and afterload), and
proper oxygenation and nutrient support [110, 117, 120, 121].
Electrical impulse propagation in the heart is regulated through the gap junctions,
which synchronize action potential progress and contraction [122]. The disruption of the
gap junction protein connexin 43 localization, or expression can trigger arrhythmias.
Continuous electrical stimulation of hiPSC-CMs has been shown to improve connexin
abundance and improve sarcomere ultrastructure [123]. The other side of the coin is the
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mechanical loading condition in culture. Mechanical cues in the native heart play an
essential role in steering physiological/pathological remodeling such as dilated or
hypertrophic cardiomyopathy [9]. The absence of electrical stimulation, preload, and
afterload in static transwell culture may partially explain the loss of contractility and
contractile protein expression after 24 hours in culture [113]. Furthermore, the high
metabolic demand of the myocardium necessitates the incorporation of rich nutrient
media. Several media supplements have been previously used to support hiPSC-CMs in
culture [124-126]. Likewise, oxygenation of the media has proven crucial to prevent
tissue hypoxia since the slice thickness (300-400 μm) approaches the diffusion limit of
oxygen of the myocardium and can heavily impact cardiac gene expression [127].
1.3.3.7 Recent efforts in creating physiological heart slice culture
In this context there have been several efforts to emulate the cardiac milieu in
culture. Watson et al. [117], investigated the application of simultaneous electrical
stimulation and preload on rat, rabbit, and failing human heart slices. The system used a
hand-operated screw and nut post to progressively stretch the tissue to different
sarcomeric lengths and achieved sub-micrometer resolution. The study compared this
system to static transwell culture and fresh tissue. Rat heart slices cultured for 24 hours
with an increased sarcomeric length of 2.2 μm showed maintained contractile function,
normal electrophysiology, conduction velocity, calcium handling, and action potential
compared to fresh tissue. Interestingly, this model showed an upregulation of
hypertrophic genes and increased calcium transient amplitude within 24 h in culture
compared to fresh heart slices. At the same time, cardiomyocyte size did not vary for all
preloading conditions tested. Five days culture with rabbit heart showed no deterioration
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in contractile function. Heart failure slices from human hearts showed some degree of
preserved contractility after 24 hours in culture.
There are obvious limitations when using slices from rat hearts since their high
metabolic rates make them more susceptible to dedifferentiation. Moreover, the short
culture time leaves unanswered questions regarding the long-term performance of static
preload. However, the improvement in functionality with stretching heart slices
underlined the undeniable mechanical stimulation role in regulating the cardiac
phenotype in-vitro. Additionally, the upregulation seen in some hypertrophic genes may
be related to the isometric contraction of the tissue slices with theoretically infinite
afterload. [128]
A reasonably similar system was developed by Fischer et al. [121] In this system,
slices from normal and failing human hearts were stretched between two posts in culture
with electrical stimulation. The heart slice was fixed at one end, while the other end was
connected to a spring cantilever to provide a linear mechanical afterload. A small magnet
coupled with a magnetic field sensor was used to detect the movement of the free end of
the tissue slice, and the contractile force was calculated in real-time using the spring
constant. While using a low stimulation frequency (0.2 Hz) for up to 4 months, the study
showed preserved contractility, preserved tissue elasticity, connexin localization, and αactinin. But there is severe downregulation of cardiac gene expression at the first assessed
time point (8 days). Unlike the culture system by Watson et al. [117], this system allowed
for active tissue contraction and shortening. Nevertheless, as noted by Pitoulis et al. [128]
this mode of contraction is still short of the physiological force-length loop where
relaxation and contraction are separated by periods of isometric relaxation and
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contraction. Ou et al. have shown that through optimized proprietary culture media,
frequent oxygenation, and electrical stimulation, tissue slices can preserve viability,
functionality, and cardiomyocyte structure for up to 6 days. [118, 120] The 300 µm
human and pig heart slices were cultured at a physiological rate (1.2 Hz, 72 beats/min)
and showed normal viability, gene expression profile, calcium homeostasis, contractility,
twitch force generation, and response to ß-adrenergic stimulation over the first six days.
However, by day 10, dedifferentiation was evident by the disruption of gene expression
of more than 500 genes, connexin-43 delocalization, and loss of contractility.
Nonetheless, prolonging functionality and maintaining cardiac phenotype for six days is a
significant advancement compared to the early transwell culture systems. However, the
critical element missing is the addition of synchronized mechanical loading of the heart
tissue.

1.4 Cardiovascular Disease
The American Heart Association (AHA) annual report on Cardiovascular Disease
(CVD) reports a 49.1% prevalence of CVD in the United States (126.9 million in 2018)
for adults > 20 years of age. [129] Mortality due to CVD was 868,662 in 2018 and
represented a $363.4 billion financial burden between 2016 and 2017. [129, 130] The
term CVD encompasses a wide range of pathologies that affect both the heart and the
vasculature. Heart diseases include Coronary Heart Diseases (CHD), heart valve diseases,
cardiomyopathies, and Heart Failure (HF). Vascular diseases include all atherosclerotic
diseases where large and medium-sized arteries are completely or partially occluded due
to the buildup of cell debris and other components to form a thrombus. [131] The
reduction or stop of blood flow may lead to end-organ failure or loss of limbs. It should
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be noted, however, that heart and vascular diseases are closely related. For example,
elevated blood pressure or hypertension can be caused by valvular as well as vascular
diseases. In turn, high arterial pressure can lead to pathological adaptation and
remodeling of the heart in order to cope with the high ventricular wall stress. The same
can happen with other types of CVD where what starts as a valvular disease (e.g., mitral,
or aortic insufficiency) or coronary blockage may lead to eventual HF.
Heart Failure
As discussed, the compensatory mechanisms of the body can lead to a gradual
worsening of the heart’s ability to efficiently pump blood throughout the circulation
leading to a vicious cycle of HF, as shown in Figure 1-8. HF can be defined as a
pathological state where a heart dysfunction diminishes the heart’s ability to pump blood
at a level that meets tissue and organ needs. [132, 133] Hemodynamically, HF is
characterized by the accumulation of blood in the atria and the venous circulation as well
as the in adequate perfusion of the end organs and kidneys, leading to water and sodium
retention.
Progression of heart failure is always associated with left ventricular remodeling,
which manifests as a gradual increase in left ventricular end-diastolic and end-systolic
volumes, wall thinning, and a change in chamber geometry to a more spherical, less
elongated shape. [134]. The subsequent heart dilation leads to increased ventricular wall
stresses that in turn cause more dilation. Myocardial infarction leads to the deposit of
collagen to compensate for myocardial death and subsequently causes ventricular
hypertrophy. In any such process, it is usually associated with a continuous decline in
ejection fraction. Additionally, sympathetic neural stimulation and the activation of the
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Renin-Angiotensin-Aldosterone System (RAAS) also lead to higher fluid retention,
increased myocardial ejection load, and ultimately further exacerbation of HF. [135]
Chronic HF affects 11% of the population aged 60-80. [129] The underlying causes
for cardiomyopathies are vast and include vascular diseases, hypertension, arrhythmias,
coronary heart diseases (ischemic cardiomyopathies), hypertrophic or dilated
cardiomyopathy, and myocarditis.[136] Therefore, the optimal therapy and preventative
approaches for HF are heavily dependent on understanding the disease etiology.
Clinically, HF manifests itself by dyspnea, shortness of breath under rest or exertion,
peripheral edema, and heart rhythm irregularities. [137] HF is classified broadly
according to left ventricular ejection fraction (LVEF) in to three categories 1) HF with
preserved ejection fraction HFpEF, (LVEF > 50%), 2) HF with midrange ejection
fraction (LVEF 41%-49%), and 3) HF with reduced ejection fraction (HFrEF), (LVEF <
40%) [138] The severity of HFrEF symptoms is commonly graded based on the New
York Heart Association (NYHA). NYHA classifies HF into four subclasses as shown in
Table 1-1. [139] The degree to which symptoms are presented directly affects the

optimal treatment option for HF patients. NYHA III and IV are considered advanced HF.
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Figure 1-8 The vicious cycle of HF reproduced from. [135] Initial injury to the heart lead
to decrease in cardiac index, and sodium and water retention. This leads to an increased
cardiac filling pressure which leads to further dilatation and remodeling of the ventricle.
Myocardial dilatation increases ventricular wall stress and remodeling which can lead to
mitral insufficiency causing decreased cardiac output and deteriorated HF condition.
Treatment of Heart Failure
The management of HF requires extraneous changes in life habits (e.g., limiting daily
fluid intake, changing traveling, dietary, and social habits), and drug therapies are usually
helpful during the initial stages. Angiotensin Converting Enzyme Inhibitor (ACE-I) is the
most recommended treatment for early-stage HF. Depending on patient-specific factors,
they can be combined with beta-adrenergic receptor blockers, diuretics, and inotropic
drugs. [13,1,2,3] In other cases, cardiac resynchronization therapy and cardioverter
defibrillators are indicated for patients with reduced ventricular function showing
abnormal sinus rhythm, AV-block and are not responding to pharmacological therapy.
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[140] The adequacy of HF treatment is obviously depending on the stage of HF as shown
in Figure 1-9. Advanced HF patients who no longer respond pharmaceutical management
and therapies are candidates for heart transplant or mechanical circulatory support using
Left Ventricular Assist Devices (LVADs) either as a bridge to transplant or a destination
therapy.

NYHA Class

Clinical symptoms

I

No limitation of physical activity. Ordinary physical activity does
not cause undue fatigue, palpitation, dyspnea (shortness of breath).

II

Slight limitation of physical activity. Comfortable at rest. Ordinary
physical activity results in fatigue, palpitation, dyspnea (shortness
of breath).

III

Marked limitation of physical activity. Comfortable at rest. Less
than ordinary activity causes fatigue, palpitation, or dyspnea.

IV

Unable to carry on any physical activity without discomfort.
Symptoms of heart failure at rest. If any physical activity is
undertaken, discomfort increases.

Table 1-1 Clinical symptoms presented by patients suffering HF. NYHA I do not present
any evidence of cardiovascular disease. There are no symptoms and limitation in ordinary
physical activity. NYHA II show mild symptoms of HF and slight limitations to their dayto-day physical activity. NYHA III patients show more severe symptoms with limitations
to ordinary activities due to symptoms with less-than-ordinary activity. Only comfortable
at rest. NYHA IV show evidence of sever cardiovascular disease with sever limitation and
experience symptoms even while at rest. NYHA III and NYHA IV are considered
advanced HF and may be candidate for heart transplant or mechanical circulatory support.
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1.5 Advanced Heart Failure Treatment
Mechanical Circulatory Support for advanced HF patients
For advanced HF patients with compromised cardiac function, heart transplantation
remains the only option to improve exercise capacity and survival. [26] but it is restricted
to select patients based on multiple factors including age, co-morbidities, and end-organ
function [141]. Further, the number of available donor organs (~2000/year in the USA)
cannot meet the growing demand (up to 30,000 per year). Mechanical circulatory support
using left ventricular assist devices (LVAD) has emerged as standard clinical therapy for
advanced heart failure due to the paucity of donor organs either as a bridge to transplant
or destination therapy. LVADs are mechanical pumps that are implanted in patients to
pump the blood from native left ventricle to the aorta to reduce ventricular workload and
augment end-organ perfusion.
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Figure 1-9 NYHA class representing different stages of HF. The recommended treatment
is shown at each stage. When all options have failed, heart transplantation or LVAD
implants are the only viable option for advanced HF. Recreated from [142]
Continuous Flow LVADs vs. Pulsatile Flow LVADs
Early LVADs were Pulsatile Flow (PF) LVADs. PFLVADs will preload and deliver
blood in a manner that is similar to the native ventricle. However, they suffered a high
failure rate due to the presence of mechanical valve, were bulky, and lead to longer postoperation hospitalization . [143, 144] Continuous Flow (CF) LVADs are smaller in size,
simpler in design, have higher durability and lower thrombosis rate. [143] It thus comes
as no surprise that CFLVADs are preferred over PFLVAD with over 95% of total LVAD
implants, 80% 1 year survival rate and 70% 2 years survival. [145] Moreover, new
generation of CFLVADs (e.g., HeartMate III, Abbott Labs, Chicago, IL) use centrifugal
pumps instead of axial flow or mixed flow impellers and magnetically levitated bearings.
The smaller size of third generation pumps obviates the need for extensive tissue
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dissection or abdominal pockets leading to simpler operation and lower reoperation rate.
[146, 147] Additionally, the non-contact nature of magnetic impeller levitation
significantly improved pump thrombosis over axial flow pumps. [146]
Diminished Pulsatility with CFLVAD support
Despite these positive clinical outcomes, the non-pulsatile nature of CFLVAD flow
has raised concerns over their chronic use. Multiple adverse events have been reported
with CFLVAD support, such as chronic closure of the aortic valve, abnormal physiologic
profile of myocardial and vascular energy utilization, gastrointestinal bleeding,
hemorrhagic strokes, arteriovenous malformations, valve fusion, and end organ failure.
[148, 149] Moreover, other studies have reported reduction in coronary flow and elevated
inflammatory response. [150, 151] For example, in a 2009 trial, the Heartmate II
CFLVAD was compared to first generation pulsatile HeartMate XVE in 200 patients.
While the survival rate was improved, 81% of patients receiving CFLVAD suffered from
organ bleeding compared to 76% with PFLVAD. [152]
These adverse vascular events, attributed to diminished pulsatility, are thought to be
caused by dysfunction of arterial endothelial cells, the primary transducers of pulsatility
in the circulatory system. [153] This body of evidence has reestablished interest in the
effects of pulsatile energy of blood flow and to explore whether it is possible to introduce
pulsatile flow modes using CFLVADs, without reverting back to unreliable, bulky
PFLVADs. Indeed, new third generation CFLVADs such as HeartMate III and
HeartWare HVAD incorporate some pulsatile mode of operation to augment arterial
pulsatility and potentially mitigate some of the adverse events seen with CFLVAD flow.
[154]
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Physiological control of LVADs
At any rate, the goal of chronic LVAD therapy is for the patient to become
independent on clinical management of their device, thus allowing improved quality of
life and home return. To achieve this, the pump must be able to adapt to the physiological
requirements of the cardiovascular system and changes in the patient’s state. [155] This
infers that the pump and pump controllers need to be sensitive to the native heart’s
preload, afterload, heartrate…, etc. The collection of this information at high fidelity,
however, is not straight forward. Implantation of pressure, flow or ventricular volume
sensors is highly undesirable because they can cause thrombus formation and are subject
to failure and sensor drift. [156, 157] Additionally, the choice of control parameters that
reflect changes in tissue metabolic demand is highly critical. In chapter 2, we develop a
sensorless control algorithm based on the pump speed to achieve physiological control of
a CFVLAD and investigate its applicability in safely producing pulse flow modulation by
ramping up and down the speed to create artificial arterial pulse.
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CHAPTER 2: SENSORLESS CONTROL OF CFLVAD USING
A MODEL OF THE CARDIOVASCULAR SYSTEM 2
2
2.1 Current State of LVAD Control
Heart failure (HF) is a progressive disease that affects 6.5 million Americans and is
the leading cause of death. Prevalence of HF is expected to rise by 46% by 2030 to an
estimated 8 million patients. The only long-term survival option for advanced heart
failure is heart transplantation, which, however, is restricted by the lack of donor organs
and the absence of comorbid conditions.[141] To bridge the supply demand gap,
CFLVADs have been used to provide mechanical circulatory support. To avoid
ventricular suction, LVADs must provide adequate blood flow and meet the cardiac
demand, which often changes with clinical and physical activity conditions (physiologic
perfusion). When pump flow does not match cardiac demand, hypoperfusion of endorgans, ventricular volume overload, pulmonary edema, and tissue hypoxia may result.
On the other hand, Over-pumping can result in ventricular suction. Ventricular suction is
caused by a reduction in pump preload, which can lead to reduced pressure in the

2

The work in this chapter has been published in [158]
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ventricle. This causes the LVAD inlet cannula to become occluded, causing myocardial
damage, pump failure, or ventricular arrhythmias that can cause adverse events or death.
With CFLVADs, physiological perfusion and suction prevention is difficult due to: (1)
nonlinearity of the circulatory system, (2) discontinuity in flows due to the valves, and (3)
increased afterload and lower preload sensitivity compared to the native heart. [160, 161],
and (4) lack of biological sensors such as baroreceptors and biological feedback
mechanisms such as sympathetic and parasympathetic response, Frank Starling
mechanism, etc. Clinically, LVADs currently do not incorporate physiologic control
mechanisms. Clinicians manually set LVAD speed setpoints based on oxygen saturation,
clinical symptoms, echocardiography, or estimated flows. [162-164] Suction detection
algorithms based on analysis of pump speed or pump current morphology are
incorporated clinically, but these algorithms can only detect suction after it has occurred
and cannot prevent suction. [165-167] Physiologic control and suction prevention have
been addressed with multiple approaches, but these require direct measurement of
pressure, flow, and ventricular volume, which requires the implantation of sensors. [168170] Sensors are prone to drift, can form thrombus, septicemia, fail and are therefore
undesirable because they increase the overall system complexity and reduce reliability.
Other approaches employ model-based parameter estimation using various of techniques
such as autoregressive exogenous modeling and Extended Kalman Filters [171-176]
Model-based methods, however, are susceptible to changes in blood viscosity, friction
forces, and impeller inertia, and are computationally expensive. Clinical studies have
shown that flow estimators have significant errors [177] and may require pressure sensors
for higher accuracy. [178] Additionally, the model parameters have to be recalculated and
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validated for different pumps and small changes in pump geometry can lead to larger
changes in pressure-flow relationship. [179] A recent study by Petrou et al. [180] looked
into the potential use of machine learning to predict blood viscosity for CFLVAD
support, but the method lacked in-vivo validation, was prone to learning error, and
increased controller complexity. A number of approaches to increase the pressure
sensitivity of rotary pumps have been proposed [181-183], but these modifications
require FDA approval and may not be applicable universally. To overcome these
limitations, this chapter introduces a simple and novel control algorithm based on the
intrinsic pump speed which can be measured using phase currents or hall effect sensors
and does not deteriorate. The control algorithm requires only maintaining the differential
pump speed (𝛥𝑅𝑃𝑀) at a user-defined value and does not require any parameter
estimation.

2.2 In-silico modeling of the cardiovascular system
The Windkessel lumped parameter representation of the cardiovascular system
models the arterial circulation as two elements: resistance element, 𝑅 and a compliance
element 𝐶. To achieve a more involved and accurate representation of the cardiovascular
system, it may be modeled as multiple 𝑅𝐶 blocks, each representing different regions of
the vascular tree. For this study, we used a network-type model which subdivides the
human circulatory system into a number of lumped parameter blocks with each block
characterized by its own resistance and compliance. [32] This model has been extensively
used and validated in literature [168, 184-187] and has been previously used for
developing timing algorithms and control systems for LVAD and BiVAD. Four
boundary conditions are defined at each block: inlet pressure, inlet flowrate, outlet
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pressure, and outlet flowrate. A schematic representation of the mathematical model is
shown in Figure 2-1.

Figure 2-1 Schematic representation of the nonlinear mathematical model used. The
cardiovascular system is simulated using twelve lumped blocks, each is defined by a
resistance and a compliance. The instantaneous volume is calculated using differential
equation (3).
Here, the divides the circulatory system into twelve blocks (left ventricle, aorta,
coronary circulation, innominate and right subclavian artery, systemic circulation, vena
cava, right atrium, right ventricle, pulmonary artery, pulmonary arterial circulation,
pulmonary venous circulation, and left atrium) and four heart valves. The model contains
5 active elements: left ventricle, right ventricle, left atrium, right atrium, and coronary
circulation whose compliances or resistances are non-linear and are a function of time
within the cardiac cycle. The four heart valves are differential pressure operated, and the
opening and closing of the valves causes a discontinuity in blood flow. Each block
consists of a storage element or compliance, (𝐶) and a resistive element, (𝑅) which can
predict the block’s volume (𝑉) and pressure (𝑃) using the following equations:
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𝑑𝑉𝑛
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are the
𝑑𝑡 is the rate of change of the volume in block n, 𝐹𝑛 and 𝐹𝑛

Where

blood flow rate in and out of block n respectively, 𝑃𝑛 is the pressure in block n. The
active compliance of the right and left ventricles are a function of time. The periodically
changing compliance introduces a change in block volume and pressure according to
𝑉

𝐶𝑛 = 𝑃𝑛 ; hence creating flow.
𝑛

Figure 2-2 Adapted from [32] . Example of active compliance element in the cardiovascular model
used. Typical left ventricular compliance is shown as a function of time. Different compliance
waveforms can be used to model the failing heart (in dotted line).
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2.3 Sensorless Speed-Based control of CFLVAD
Study Hypothesis
To avoid unreliable sensor implantation or complicated or inaccurate model-based
estimations, a sensorless controller for CFLVAD that is based solely on the intrinsic
pump speed was developed. The hypothesis is based on the observation that the
pulsatility in the pump speed signal is a measure of the degree of ventricular preload. As
shown in Figure 2-3, At low pump flow, the differential pump speed (𝑅𝑃𝑀𝑚𝑎𝑥 −
𝑅𝑃𝑀𝑚𝑖𝑛 ) is increased. This is because the heart filling volume increases which leads to
more blood being pushed out by the ventricle through the pump inlet. The opposite effect
takes place when the pump speed is increased and the amount of blood inside the
ventricle is reduced. This in turn reduces the blood that is being pushed by the ventricle
contraction to the pump inlet. Based on this observation, it may be possible to use the
differential pump speed, 𝛥𝑅𝑃𝑀 as a marker for ventricular preload and tissue demand
and thus adjust flow accordingly.

Figure 2-3 Pump flowrate pulsatility at different rotational speeds. As the pump speed
increases the pulsatility(i.e., ΔRPM) of the VAD flowrate and VAD speed (not shown)
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decreases and the pump approaches suction. When the pump speed decreases, the VAD
flowrate and speed pulsatility will increases. Source: HeartWare HVAD training manual.
Controller structure and objectives
The controller objective to maintain a fixed differential pump speed (𝛥𝑅𝑃𝑀) to avoid
suction events during reduced preload, while producing sufficient perfusion at exercise
and rest. The control system relies solely on noisy measurements of pump speed 𝛥𝑅𝑃𝑀𝑛 ,
which can be measured using phase currents or hall effect sensors. For modelindependent control, a moving average filter (window size =8 data points) was used to
filter the rotor speed measurement. Using PI controllers, the differential pump speed
setpoint was maintained using the following equation:

𝐼 = −𝐾𝑝 (ΔRPM𝑟𝑒𝑓 − ΔRPM𝑓 ) −

𝐾𝑝 𝑡
∫ (ΔRPM𝑟𝑒𝑓 − ΔRPM𝑓 )𝑑𝑡
τ 0

(4)

where 𝐼 is the pump current, ΔRPM𝑟𝑒𝑓 is the reference differential pump speed and
ΔRPM𝑓 is the filtered differential pump speed at any instant, 𝐾𝑃 and 𝜏 are the
proportional and integral gains, respectively. It is important to note that the (4) is due to
the inverse relation between pump speed pulsatility and ventricular loading. High pump
speed pulsatility implies low ventricular unloading and low pulsatility implies a high
ventricular unloading. The PI-controller gains were tuned a priori using a direct
numerical search approach [188]. 𝐾𝑃 was set to 0.00025, and 𝜏 was set to 5. ΔRPM𝑛 was
calculated as the difference between the maximum and minimum noisy RPM values
during a moving time window of the preceding two seconds. ΔRPM𝑟𝑒𝑓 was set to 800
RPM. The control schematic is shown in Figure 2-4.
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Figure 2-4 Published in [159] Control schematic for the proposed ΔRPM controller.
Measured of the noisy pump speed are filtered and the filtered ΔRPM is fed to the PI
controller in equation (4) which work to maintain a physiologically relevant pump speed
differential.

2.4 Benchmark Testing and Study Methods
Mathematical model of CFLVAD
In order to incorporate the CFLVAD controller in-silico, models developed by Choi et
al. [189] and Krishnan [190] were used to simulate the CFLVAD. In this model, a
dynamic axial flow pump is driven by a brushless dc motor and the model for the
brushless dc motor is given by

𝐽

𝑑𝜔 3
= 𝐾 𝐼 − 𝐵𝜔 − 𝑎0 𝜔3 − 𝑎1 𝐹𝑃 𝜔2
𝑑𝑡 2 𝐵

(5)

Where 𝐽 is the rotor inertia, 𝜔 is the rotor speed in rad/s, 𝐾𝐵 is the back electromotive
force constant, 𝐼 is the phase current, 𝐵 is the damping coefficient, 𝑎0 and 𝑎1 are
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correlation constants, and 𝐹𝑃 is the pump flow in ml/s. The brushless DC motor is
couple with a model for the axial flow pump, which is given by
𝑑𝐹𝑃
𝑏0
𝑏2
1
= − 𝐹𝑃 − 𝜔2 + 𝛥𝑃
𝑑𝑡
𝑏1
𝑏1
𝑏1

(6)

𝑏0 , 𝑏1 , and 𝑏2 are experimental constants and 𝐹𝑃 is the pump flow rate. The equation
parameters are experimentally characterized and given as:
𝑚2

𝑠

𝐽 = 9.16 × 10−7 𝐾𝑔. 𝑚2 , 𝐾𝐵 = 0.003𝐾𝑔. 𝐴.𝑠2 , 𝑎0 = 7.38 × 10−13 𝐾𝑔. 𝑚2 . 𝑚𝑙3 , 𝐵 =
6.6 × 10−7 𝐾𝑔.

𝑚2
𝑠

𝑠

𝑠

, 𝑎1 = 1.98 × 10−11 𝐾𝑔. 𝑚2 . 𝑚𝑙 , 𝑏0 = −0.296 𝑚𝑚𝐻𝑔. 𝑚𝑙 , 𝑏1 =

𝑠2

−0.027 𝑚𝑚𝐻𝑔. 𝑚𝑙 , 𝑎𝑛𝑑 𝑏2 = 9.33 × 10−5 𝑚𝑚𝐻𝑔. 𝑠 2 .
In the context of the lumped parameter model of the cardiovascular system , the
CFLVAD is incroportated flow path from the left ventricle to the aorta as shown in
Figure 2-4. In order to demonstrate pump independency, we have implemented the
ΔRPM controller using Deltastream mixed flow Pump (DP2), Medos AG,Stolberg,
Germany. For the DP2 pump, we used the pump model developed by Petrou et al. [191].
The pump equations for the DP2 pump
are:
𝑑𝜔
𝑑𝑡

1

= 𝐽(𝜔) (𝐾𝑇 𝐼 − 𝑔1 (𝜔) + 𝑔2 𝜔 − 𝑔3 𝜔2 − 𝑔4 𝐹𝑃 𝜔 )

(7)

and
𝑑𝐹𝑃
𝑑𝑡

1

= − 𝐹 (−𝛥𝑃 + 𝑓1 𝜔2 − 𝑓2 𝐹𝑃 − 𝑓3 𝐹𝑃 2 )

(8)

Where𝑓1 , 𝑓2 , 𝑓3 , 𝐾𝑇 , 𝑔1 (𝜔), 𝑔2 , 𝑔3 𝑔4 , 𝐽(𝜔), 𝑎𝑛𝑑 𝐹 are coefficients adapted from [191] are
given as
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𝑓1 =

6.572 × 10−6

𝑚𝑚𝐻𝑔⁄𝑅𝑃𝑀2

𝑓2 =

2.071

𝑚𝑚𝐻𝑔⁄𝐿/𝑚𝑖𝑛

𝑓3 =

1.043

𝑚𝑚𝐻𝑔⁄(𝐿/𝑚𝑖𝑛)2
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𝐹=

0.8596
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𝐿
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Comparison with Sensorless Control Algorithms
The robustness analysis was performed by introducing different levels of normally
distributed noise (1%-10%) to the pump speed at 100-Hz sampling frequency. Two
sensorless algorithms previously proposed were compared to the 𝛥𝑅𝑃𝑀 algorithm: (1) a
constant speed algorithm and (2) a constant differential pressure algorithm, 𝛥𝑃𝑑 (pressure
difference between left ventricle and aorta). Constant speed control is the current clinical
standard. This control mode was achieved by setting the pump speed to 10700 RPM set
point using PI controller (𝐾𝑃 = 0.0028, 𝜏 = 5). The constant speed controller is referred
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to as the constant RPM controller. In differential pressure controller, 𝛥𝑃𝑑 was estimated
using the method described in [174]. ΔP𝑑 was estimated using the measured pump speed,
the estimated pump flow 𝐹𝑃 , a Golay-Savitzky (GS) filter and an extended Kalman filter
(EKF). 𝛥𝑃𝑑 reference set point was set to 87 mmHg. The differential pressure controller
had a gain, 𝐾𝑃 = 0.003, time constant, 𝜏 = 5, and used a low-pass Butterworth filter with
a 5-Hz cutoff frequency. The differential pressure controller will be referenced as, ΔP
control.
Comparison with Sensor-Based Control Algorithms
In addition to other sensorless controllers, 𝛥𝑅𝑃𝑀 control algorithm was compared to the
following sensor-based LVAD control algorithms proposed in literature: (1) control based
on left ventricular end diastolic pressure (LVEDP) [192] and (2) control based on mean
aortic pressure (MAOP)[193]. Mean aortic pressure control was achieved by setting the
reference MAOP to 100 mmHg at which the pump flow was 5 l/min at rest. The gain, 𝐾𝑃
was set to 0.04, and time constant, 𝜏 = 5. T Controlling left ventricular end diastolic
pressure used a constant reference pressure of 7 mmHg at which the pump provided
approximately 5 l/min at rest and used a constant reference pressure system and used 𝐾𝑃 =
0.05, 𝜏 = 5. Efficacy and robustness of all algorithms were tested in-silico using (1) rest
and exercise conditions, (2) a rapid eight- fold increase in pulmonary vascular resistance
(PVR) under rest and exercise, (3) transitions from rest to exercise and exercise to rest, (4)
safe mode during left heart fibrillation, and (5) 1% to 10% RPM measurement noise
through (1) to (4). (4) and (5) were only applied to the proposed 𝛥𝑅𝑃𝑀 control.
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Safe Mode
𝛥𝑅𝑃𝑀 control is based on the pulsatility of the pump speed which is caused by the
reserve native contractility of the left ventricle. In the event of an asystolic heart, the ΔRPM
controller was designed to switch to a safe mode which will switch to a constant RPM
when the mean pump speed drops below a certain threshold (8000 RPM) for longer than
10 seconds. Asystolic heart will diminish the pump speed pulsatility and the ΔRPM
controller will work to reduce pump speed. This can lead to hypoperfusion, mortality and
pump thrombosis. The safe mode maintains the mean pump speed at 8500 RPM to prevent
pump stoppage and thrombosis in dangerous conditions.
Introducing a pulse flow modulation mode to augment arterial pulsatility
using 𝚫𝐑𝐏𝐌 control algorithm
The small size, easier implantation, and low failure rate of CFLVADs made them the
favorable option over first generation PFLVADs. However, as discussed in 1.5.3, the
adverse events associated with diminished pulsatility during CFLVADs chronic use have
prompted pump manufacturers to incorporate pulsatile modes of operation to augment
arterial pulsatility. Without proper control, these modes are vulnerable to the same
disadvantages of constant speed pump control. To show the versatility of the ΔRPM
controller, a flow modulation mode was developed that was based on the measurement of
ΔRPM during pump operation. The control scheme is shown in Figure 2-5 below. The
goal of the algorithm is to safely incorporate artificial pulsatility in the ΔRPM controller
while avoiding ventricular suction and providing adequate perfusion. Here, ΔRPM was
modulated between 900 RPM and 1800 RPM. This was achieved by ramping the pump
speed up and down between 12000 and 7500 RPM at rate of 1800 𝑅𝑃𝑀/𝑠 2 . This was
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thought to be sufficient to achieve a pulse frequency >10 beat/min at rest. It is important
to note that the algorithm will switch the pulse primarily based on the measured ΔRPM
signal. In that way, the pump is protected against excessive suction or reduced perfusion.
The asynchronous pulse flow modulation strategy was tested 1) during rest, 2) during
exercise, 3) 5x PVR during rest and exercise, and 4) 1%-5% noise during all conditions.

Figure 2-5 [194] 𝛥𝑅𝑃𝑀 pulse flow modulation mode developed. The pump speed is
ramped between two limits using a PI control structure. An upper and lower 𝛥𝑅𝑃𝑀 limits
are put to ensure safe pulsatile operation which avoids ventricular suction, low perfusion,
and diminished pulsatility.
Data Analysis
MATLAB (MathWorks, Natick, MA, USA) was used to calculate the hemodynamics and
CFLVAD parameters. Aortic systolic, diastolic, and mean pressures, end systolic and end
diastolic pressures, and aortic flow rate were computed as part of the data analysis. In
clinical practice, the left ventricular end diastolic diameter or pressure is used to define
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suction [195]. Consequently, a suction event occurs when the ventricular end diastolic
pressure is less than 2 mmHg.

Results

Exercise

Rest

The proposed controller (𝜟𝑹𝑷𝑴 control)

NH baseline
FH baseline
ΔRPM ctrl
CS ctrl
ΔP ctrl
EDP ctrl
MAOP ctrl
NH baseline
FH baseline
ΔRPM ctrl
CS ctrl
ΔP ctrl
EDP ctrl
MAOP ctrl
ΔRPM ctrl
CS ctrl
ctrl
EDP ctrl
MAOP ctrl
ΔRPM ctrl
CS ctrl

Exercise 8x PVR Rest- 8xPVR
PVR

2.5

ΔP ctrl
EDP ctrl
MAOP ctrl

LTO
(L/min)

AoP
(mmHg)

LVEDP
(mmHg)

LVV (ml)

min
(mmHg)

5.0
3.7
5.0
5.0
4.9
5.0
5.0
8.2
6.1
8.0
7.6
7.9
8.1
7.6
5.0
4.7
4.6
4.3
-*
7.0
7.14
7.3

122/78
96/63
104/100
104/100
103/98
102/97
103/98
129/84
102/65
108/104
103/98
106/102
108/105
104/98
104/100
95/94
93/91
90/85
100/99.9
96/92
96/93
98/95
96/92

8
16
5.6
5.4
6.6
7
6.3
6.4
21
7.4
10
8.2
7.0
10.2
5.6
0.9(-0.2)
2.5(0.8)
7(4.4)
-3.7(-3.7)
7.2(4.6)
6.2(5.0)
4.8(3.0)
7(5.1)

85/147
181/229
40/65
36/63
49/77
53/82
46/74
45/112
190/242
58/94
88/12
68/104
54/89
89/126
40/65
2/11
14/34
55/82
-*
58/91
49/80
32/63
56/89

5
9.5
3.5
3.3
4.4
4.8
4.1
3.0
16.4
5.2
7.8
6.0
4.9
7.8
3.51 (3.1)
0.37 (-0.7)
1.5 (0.4)
4.8 (3.7)
-4.4 (-4.4)
5.2 (3.1)
4.5 (3.5)
3.3 (1.8)
5.0 (3.5)

No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Yes
Yes (IS)
No
Yes
No
No
No
No

101/100

2.0(2.8)

9.3/32

1.4 (1.9)

Yes

7.1
7.6

LVP
Suction

Table 2-1 Published in [159] Control outcomes during multiple test conditions using the
proposed controller as compared to four different controllers from literature. LTO: Left
Total Output, AoP: Aortic pressure, LVEDP: Left ventricular end diastolic pressure, LVV:
Left ventricular volume. LVP: Left ventricular pressure, IS: Intermittent suction. Values
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in parenthesis are the minimum transitional values during 8x PVR. ΔRPM ctrl: speed
pulsatility control, ΔP ctrl: differential pressure control CS ctrl: constant speed control,
EDP ctrl: end diastolic pressure control, MAOP ctrl: mean aortic pressure control. * Note
that during high levels of ventricular suction as in the MAOP control with reduced preload,
the pump flow rate and ventricular volumes are variable and thus are not included in the
table.

Compared to other controllers tested, 𝛥𝑅𝑃𝑀 control provided physiologic perfusion and
prevented ventricular suction in all test conditions. During rest 𝛥𝑅𝑃𝑀 control provided 5
l/min and 8 l/min during exercise. As shown in Table 2-1 and Figure 2-6, 𝛥𝑅𝑃𝑀
algorithm prevented ventricular suction during a rapid 8x increase in pulmonary vascular
resistance (PVR). During 8x PVR, the end diastolic pressures were 5.6 mmHg and 7.4
mmHg at rest and exercise respectively.
The controller adapted well to instantaneous transitions from rest to exercise and
exercise to rest, Figure 2-8. It only took less than 60 seconds for the controllers to reach
95% of the steady state values in all tested cases. The 𝛥𝑅𝑃𝑀 control algorithm achieved
similar results with the DP2 pump during rest and exercise, and prevented ventricular

ΔRPM controller

suction with 8x PVR, Figure 2-9.
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Constant Speed control
ΔP controller
MAOP Control

Figure 2-6 Published in [159] Controller response comparison during rapid
reduction in preload (8x PVR). The preload reduction was introduced at t=150s for
the ΔRPM, constant RPM, ΔP, and MAOP controllers. Constant suction is evident
in constant speed control with end diastolic pressures below 1mmhg at steady state.
ΔP control caused intermittent suction during transition, but soon recovered
afterwards. MAOP control, cause excessive constant suction. The proposed ΔRPM
controller maintained the highest safety margin at steady state and during transition
as seen with ventricular volume and pressure waveforms. AoP: Aortic pressure,
LVP: Left ventricular end diastolic pressure, LVV: Left ventricular volume, LAP:
Left atrial pressure, MAOP: Mean Aortic Pressure.
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Constant RPM control (Clinical standard)
During rest, constant RPM control provided mechanical unloading of the heart
and provided (5.0 l/min) without suction events and maintained LVEDP at 5.4 mmHg.
During exercise, the constant RPM control slightly augmented the pump flow (7.6 l/min)
but to a lower degree than the normal heart and ΔRPM control flow augmentation.
Significantly, during the rapid increase in PVR, constant RPM control caused suction at
rest (steady state LVEDP = 0.9 mmHg, with a LVEDP as low as -0.2 mmHg during
transition), Figure 2-6. Suction did not occur during exercise with an eight-fold increase
in PVR with a minimum ventricular pressure of 3.1 mmHg. Transitions from rest to
exercise and exercise to rest also did not trigger ventricular suction.
𝜟𝑷 control (model-based estimation)
While 𝛥𝑃 control supplied adequate perfusion during rest (4.93 l/min) and exercise
(7.9 l/min), intermittent suction (IS) happened during 8x PVR increase at rest (0.8 mmHg
LVEDP during transition), Figure 2-6, and soon recovered to 2.5 mmHg at steady state.
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𝛥𝑃 controller adapted well to instant transitions from exercise to rest and rest to exercise
without any suction events.

1%
4%
6%

Rest
Exercis
e
Rest 8x
PVR
Rest
Exercis
e
Rest 8x
PVR
Rest
Exercis
e
Rest 8x
PVR

Actual
ΔRPM
798
818

Filtered
ΔRPM
793
766

LVEDP
(mmHg)
5.6
7.4

LTO
(l/min)
5.0
8.0

817

764

7.1(4.6)

4.4

No

667
622

711
684

4.8
6.3

5.0
8.1

No
No

596

665

3(1.5)

4.3

No

398
455

745
667

3.2
4.8

5.3
8.2

No
No

513

723

2.8(-0.2)

4.5

Yes (IS)

Suction
No
No

Table 2-2 Published in [159] Noise tolerance of the proposed
ΔRPM control algorithm with 1%, 4%, 6% normally distributed
noise. Values in parenthesis are the minimum transitional values
during 8x PVR. After 6% noise, control deteriorated, and
intermittent or constant suction events occurred.
MAOP control (sensor-based control)
MAOP control with as set point at (100 mmHg) led to adequate perfusion during rest (5.0
l/min) but could not provide adequate perfusion during exercise (7.6 l/min). The MAOP
control failed to adapt during reduced preload condition (8x PVR) with the onset of
constant suction and negative LVEDP as shown in Table 2-1.
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EDP control (sensor-based preload control)
EDP control led to adequate perfusion during rest (5 l/min) and exercise (8.1
l/min) as well as protection against suction during reduced preload and instantaneous
transition from exercise to rest and rest to exercise. This is expected since a control based
on preload is effectively mimicking the natural Frank-Starling mechanism. However,
EDP control performance deteriorated with the introduction of sensor drift as low as 5
mmHg (with zero measurement noise), which is below the reported drift for similar
inlet/outlet sensors[156, 157], and intermittent suction occurred when using 8x PVR.
Higher levels of sensor drift caused constant suction, as shown in Figure 2-7.

Controllers from literature
Proposed 𝜟𝑹𝑷𝑴 controller

EDP control, no noise or drift
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EDP control, no noise, 5
mmHg drift

Figure 2-7 Published in [159] Control comparison using EDP control with and without a
5mmHg inlet pressure sensor drift during 8x PVR. Intermittent suction is seen transitionally as
the left ventricular volume and pressure fall rapidly but soon recover. Current implantable
pressure sensor technologies have reported >4x higher sensor drifts in 1 year. It is important to
note that for EDP control was used with a single EDP reference point.

Noise tolerance
To illustrate the noise tolerance of the proposed algorithm, 𝛥𝑅𝑃𝑀 control tested
with different levels of measurement noise. The controller was able to provide
physiologic perfusion and suction prevention with eight-fold PVR at rest with up to 6%
noise while only using a moving average filter, as shown in Table 2-2. The controller
caused intermittent suction with 7%, 8% and the control quality deteriorated completely
with 10% noise. Any noise level greater than 6% caused some degree of suction or
intermittent suction.

Rest to exercise

Exercise to rest
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Safe mode

Figure 2-8, Published in [159] hemodynamic results using the proposed controller (ΔRPM
controller) during transition from rest to exercise and exercise to rest at t=100s, and during
asystole (t=70s). The safe mode is triggered when the pump speed drops below 8000 RPM for
longer than 10s. A constant speed control then maintains the pump speed at 8500 RPM which
reverts the heart to HF baseline.

Safe mode
When the pump speed dropped below 8000 RPM for more than ten seconds, the
safe mode detected the onset of asystole. Automatically, the controller switched to a
constant speed control and maintained the pump flow rate at 3.7 l/min, which is
equivalent to the output of an unassisted failing heart (see Table 2-1) and caused no
suction at rest. Figure 2-8 shows the safe mode in which left heart asystole is induced at
t=70s and the controller maintains at rest a mean pump speed of 8500 RPM.
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Pulsatile mode using 𝜟𝑹𝑷𝑴 control
Axial Flow Pump

Mixed Flow Pump

Figure 2-9 Published in [159] Suction prevention during reduced preload (8X PVR)
with an axial flow pump and mixed flow pump. Increased PVR was initiated at t=150 s.
The controller successfully prevented suction for both pumps with 1% normally
distributed noise.
Pulse flow modulation provided adequate perfusion at rest (5.1 L/min) and
prevented ventricular suction with 5x PVR increases. The dynamic modulation strategy
resulted in ~30 mmHg of arterial pulse pressure (115/85 mmHg) and 10 beats/min pulse
frequency, Figure 2-10. At 5x PVR, no intermittent suction was noticed transiently, and
the minimum ventricular pressure did not drop below 1 mmHg as shown in Figure .
Similarly, during exercise, the CFLVAD augmented blood flow and provided 8.0 L/min,
28 mmHg pulse pressure at 7 beats per minute (Figure 2-10), and prevented ventricular
suction at 5x PVR, Figure 2-11. The pulsatile mode was able to provide normal,
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physiological perfusion at rest with up to 3% noise. However, at 4% speed measurement
noise, intermittent suction was seen with 5x PVR transitionally, and was persistent with
5% noise.
Rest

Exercise

Figure 2-10 [194]Pulsatility augmentation mode using ΔRPM control algorithm
during rest and exercise. Pulse pressure was increased to 30 mmHg at rest and 28
during exercise.
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Figure 2-11 [194] 5-fold rapid increase in PVR during rest with pulsatility
augmentation did not result in suction event. 5x-PVR increase was simulated at t =
100s.

Figure 2-12 [194] 5-fold rapid increase in PVR during exercise did not cause
ventricular suction with pulsatile mode turned on. The onset of PVR increase was
initiated at t =100.

2.6 Discussion
Novelty and significance of the 𝚫𝐑𝐏𝐌 Control Algorithm
A set of in silico experiments demonstrated the feasibility of adapting pump flow
to physiologic demand and preventing ventricular suction when the proposed ΔRPM
control algorithm is employed. One of the novel aspects of the proposed algorithm is the
choice of the control variable (ΔRPM) that, even with a simple PI controller, can produce
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physiological control and suction prevention with only a single constant ΔRPM setpoint.
It is important to note that the ΔRPM control achieved adequate perfusion both at rest and
during exercise and prevented suction both during rapid changes in preload (eightfold
increase in PVR) as occurs with the Valsalva maneuver or during coughing but to a lesser
extent. The proposed control algorithm demonstrated superior performance over the
current clinical standard using constant speed control, where ΔRPM control provided
greater flow or equivalent resistance to suction. Adding to that, we implemented the
proposed algorithm using a mixed flow pump (DP2) and achieved similar results and
adequate perfusion suction prevention, demonstrating that the algorithm is independent of
the pump design., Figure 2-9.
Effectively, the ΔRPM control synchronizes the ventricular assist provided by the
LVAD with the natural control mechanisms of the body. For instance, increased venous
return during exercise will increase preload and ventricular contractility due to the FrankStarling mechanism. An increase in ventricular contractility leads to an increase in ΔRPM
, which will cause the controller to increase the pump speed and flow in order to maintain
the desired ΔRPM setpoint. Reduced perfusion demand would reduce contractility,
causing the controller to reduce the pump speed and flow, preventing over pumping and
suction. Accordingly, the control algorithm uses the body's own sympathetic and
parasympathetic control mechanisms to match perfusion demand and avoid suction.
Comparison with Novel Physiological Controllers in Literature
Preload control has been proposed in the literature (e.g., [196, 197]). These
systematic approaches have included direct measurements of preload (end diastolic
pressure [196], end diastolic volume [197]), combined ventricular pressure and afterload
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impedance estimation [198], or heart rate and aortic pressure estimations. [192] In these
controllers, A single reference point can be sufficient in preventing ventricular suction
and ensuring adequate perfusion in these controllers [199]. However, direct measurement
requires pressure or ventricular volume sensors, which have low long-term reliability and
drift [156, 157]. As a result, these sensors have not been chronically tested in vivo. In our
study, even when a 5mmHg drift was introduced to the measurement, EDP control
resulted in intermittent suction, Figure 2-7.
Based on the measurement of aortic pressure, Wu et al. attempted to achieve
physiologic control by measuring only afterload [200]. The strategy of maintaining a
reference mean aortic pressure provided adequate perfusion at rest and during exercise,
but did not prevent suction because it does not allow for ventricular filling and causes
suction (Figure 2-6, Table 2-1). Several control schemes have modified such control to
account for both preload and after load (e.g. [201]and [198]).
Salamonsen et al. [202] have shown that the relationship between pump speed and
pump speed pulsatility is linear when the aortic valve is closed. In partial support, this
linearity is lost. Specifically, they chose flow pulsatility over pump speed pulsatility as a
measure of preload because flow pulsatility maintained a more linear relationship during
partial support. However, pump speed pulsatility is readily available whereas pump flow
must be estimated. Furthermore, parametric, and model-based methods used to estimate
pump flow are reported to be unreliable and inaccurate, as well as being susceptible to
changes in blood viscosity [203].
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Introduction of Pulsatility augmentation
Pulse flow modulation strategies have been proposed as a possible solution to the
lack of pulsatility in CFLVAD flow regime. The advantages of CFLVADs use make
reverting to older PFLVAD undesirable, and therefore modulating CFLVAD speed is a
possible compromise to stop the adverse events associated with diminished pulsatility.
Pulsatility augmentation can be performed either synchronously, or asynchronously. In
synchronous pulse flow modulation, sensors have to be implanted to identify the cardiac
timing in order to increase the pump flow in synchrony with the native heart ejection. The
disadvantage of this method is 1) it requires sensor implantation or sophisticated ejection
estimation algorithm, and 2) the pulsatility augmentation with synchronized flow
modulation will inherently be limited because the peak pump flow in commercial
CFLVAD is ~10 L/min, while the peak instantaneous flowrate in the healthy heart is ~30
L/min. Alternatively, asynchronous pulse modulation can provide higher levels of
pulsatility, regardless of the heart state at a lower frequency.
Here, we show the feasibility of achieving pulse flow modulation using the
𝛥𝑅𝑃𝑀 algorithm. We also demonstrate its robustness with up to 3% and sudden decrease
in preload (5x increase in PVR). The advantage of using 𝛥𝑅𝑃𝑀 as the control objective
is that while it allows variation of the pump speed to induce arterial pulsatility, it provides
inherent protection against ventricular suction and reduced end organ perfusion.
Altogether, the 𝛥𝑅𝑃𝑀control algorithm can simultaneously meet 3 goals 1) Provide
physiological perfusion that is responsive to tissue demand, 2) prevent ventricular suction
during reduced preload, and 3) augment arterial pulsatility to potentially prevent the
adverse events associated with CFLVAD flow.
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Advantages of the proposed Algorithm
In order for the proposed controller to perform adequately, it is essential to select
an appropriate setpoint for the 𝛥𝑅𝑃𝑀. Having a high 𝛥𝑅𝑃𝑀 setpoint may result in
reduced perfusion, while a low 𝛥𝑅𝑃𝑀 setpoint may result in ventricular suction. In our
simulations, however, we have demonstrated that the appropriate choice of a single
𝛥𝑅𝑃𝑀 setpoint can simultaneously meet both physiologic control and suction prevention
objectives. As the control algorithm requires only measurement of pump speed, which is
an intrinsic pump parameter, it is unnecessary to install unreliable pressure or flow
sensors. Furthermore, it does not require frequent adjustments to setpoints (e.g., pump
speed). Moreover, apriori estimation of pump models is not required, which eliminates
errors arising from the patient's blood viscosity fluctuations or circadian variations. It is
important to note that the proposed algorithm does not detect suction. Rather, it detects
the approach of suction and reduces the pump speed accordingly. Additionally, the
algorithm does not require any modifications to the design of blood pumps, and it can be
readily incorporated into existing systems.
It is possible to measure the speed of the rotor using phase currents or hall effect
sensors, which typically have a noise level of no more than 1%. In spite of up to 6%
noise, the controller maintained physiologic perfusion, demonstrating its robustness
(Table 2-2). The simplicity of the control structure is directly related to its control
objective, which is based on pump speed pulsatility. When the differential pump speed is
controlled, there are no limits to the mean pump speed, which ensures adequate pump
flow and perfusion during rest and exercise or during vascular changes, provided that no
suction is generated. Thus, the controller can cope with the temporal variations associated
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with the cardiovascular system (for example, circadian variation and intra-patient
variations). While pump speed pulsatility was used in this study, other intrinsic pump
parameters that are sensitive to pressure head changes across the pump (e.g., changes in
pump current) may also be used for physiologic control and suction prevention.

2.7 Alternative method to use pump speed pulsatility
In the previous sections, pump speed pulsatility was used directly and was
quantified as the difference between the maximum and minimum pump speed over the
past 2 seconds (𝛥𝑅𝑃𝑀 = 𝑃𝑆𝑚𝑎𝑥 − 𝑃𝑆𝑚𝑖𝑛 |𝛥𝑡=2𝑠 ). Where PS is the pump speed in RPM.
The limitation is that 𝛥𝑅𝑃𝑀 as calculated here is susceptible to noise spikes and
measurement error. Alternatively, different quantifications of pulsatility can be used. To
postulate that, an effective Suction Index (SI) that can be extracted from the noisy pump
speed measurement is introduced. A 5-second moving window can be used to calculate
the suction index as

𝑆𝐼 =

𝑚𝑎𝑥[𝑑𝑃𝑆⁄𝑑𝑡]
𝑚𝑒𝑎𝑛[𝑃𝑆]

|
𝛥𝑡=5𝑠

Similar to the 𝛥𝑅𝑃𝑀 control structure, the same control structure (equation 4) can be
adapted to SI control using a gain scheduled PI controller, which enables the use of a
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(9)

fixed control configuration, and it only needs selection of the controller coefficients and
setpoints. The control equation becomes

𝐼 = 𝐾𝑝 (SI𝑟𝑒𝑓 − SI𝑓 ) +

𝐾𝑝 𝑡
∫ (SI𝑟𝑒𝑓 − SI𝑓 )𝑑𝑡
τ 0

(10)

To illustrate the feasibility and versatility of pulsatility control, SI control was
implemented in Heart Mate II axial flow pump. SI reference point was set to 0.8, 𝐾𝑝 =
0.55, τ =5, and was tuned a priori with a direct numerical search approach. [204]
As shown in Figure 2-13, SI was extracted from the noisy pump measurement.
The SI control variable was tested during rest and exercise with up to 8x-PVR, and
during sudden transitions from rest to exercise. The control algorithm performed similar
to 𝛥𝑅𝑃𝑀 control and augmented flow from 5.0 L/min during rest to 8.5 L/min during
exercise as shown in Table 2-3 which is slightly superior to ΔRPM . Figure 2-14
demonstrated that the controller was able to prevent LV suction during a rapid eight-fold
increase in PVR. The controller also effectively achieved rapid transitions from exercise
to rest Figure 2-15 without inducing suction.

Figure 2-13 Published in [158] The suction index (SI) extracted from the noisy pump
speed measurement. Under SI control, mean Suction Index is kept at 0.8 ± 0.2.
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Rest
Exercise
Rest,8xPVR
Exercise,
8x-PVR

LTO (L/min)

AoP (mmHg)

LVEDP (mmHg)

LVV (ml)

Suction

NH baseline
FH baseline
ΔRPM ctrl
IS ctrl
NH baseline
FH baseline
ΔRPM ctrl
SI ctrl

5.0
3.7
5.0
5.0
8.6
6.7
8.0
8.5

122/78
96/63
104/100
104/100
121/74
95/58
108/104
97/94

8
16
5.6
5.4
6.6
20.1
7.4
7.0

85/147
181/229
40/65
36/63
42/114
178/234
58/94
53/82

No
No
No
No
No
No

ΔRPM ctrl

5.0

104/100

5.6

40/65

No

SI ctrl

4.4

91/86

5.5

42/65

No

ΔRPM ctrl

7.0

96/92

7.2

58/91

No

SI ctrl

7.2

84/80

6.6

53/77

No

No

Table 2-3 Published in [158] Control outcomes during multiple test conditions
comparing results from 𝛥𝑅𝑃𝑀 and IS control. The results show comparable control
outcome from both algorithms. AoP: Aortic pressure, LVEDP: Left ventricular end
diastolic pressure, LVV: Left ventricular volume. ΔRPM ctrl: pump speed pulsatility
control, IS ctrl: Suction Index control.

Figure 2-14 Published in [158] SI control performance during 8x-PVR. The rapid
increase in PVR was initiated at t= 300s. The controller responded by quickly decreasing
the pump current to maintain the set reference SI (SI = 0.8) and prevented ventricular
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suction. AoP: Aortic pressure, LVP: Left ventricular pressure, LVV: Left ventricular
volume.

Figure 2-15 Published in [158] SI control performance during transition from exercise to
rest. The transition was initiated at t = 300s. The algorithm adapted quickly, prevented
suction, and provided adequate perfusion at rest. AoP: Aortic pressure, LVP: Left
ventricular pressure, LVV: Left ventricular volume.
SI can be determined from noisy RPM measurements with a uniformly distributed
noise of 2%, regardless of the physiologic conditions. As with the 𝛥𝑅𝑃𝑀 algorithm, SI
control synchronizes the assist with the native ventricular function based on the native
ventricular contraction. By way of example, increased preload and exercise leads to a
higher ventricular contractility due to the Frank Starling mechanism. A higher ventricular
contractility results in a higher 𝑚𝑎𝑥[𝑑𝑃𝑆⁄𝑑𝑡] and SI value. The SI pump controller will
in turn increase the pump current and help match the perfusion demand.
These results show that sensorless control based on pump speed pulsatile response
to reserve cardiac contractility can be harvested in multiple forms by extracting different
features as was illustrated in 𝛥𝑅𝑃𝑀 and SI-based control.
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2.8 Limitations
Pulsatile control requires the LVAD to respond to pressure head changes and
maintain some degree of contractile reserve throughout a cardiac cycle. Even in patients
with end-stage heart failure (~15-20% ejection fraction), the native cardiac contractility is
sufficient to cause changes in pump speeds, as demonstrated in this study. However, the
proposed controller will fail during ventricular asystole/fibrillation when ventricular
contractility becomes negligible, and the heart rate falls. Low 𝛥𝑅𝑃𝑀 would result in the
controller reducing the pump speed and flow below physiological levels. To mitigate this,
a safe mode was implemented to maintain a constant pump speed in the event of left heart
asystole to maintain pump flows at basal levels (heart failure baseline) and potentially
sustain life while avoiding pump thrombosis and suction. The lack of ventricular
contraction in asystole/fibrillation results in a low 𝛥𝑅𝑃𝑀, which the controller responds
to by reducing the RPM. However, even if the RPM value is at the lowest clinically
recommended RPM of the pump, the 𝛥𝑅𝑃𝑀 value will not increase, as there is no
effective contraction of the myocardium. To accomplish this, the safe mode operates at a
clinically recommended minimum RPM to minimize the risk of pump thrombosis while
ensuring ~3.7 L/min of flow, which is equivalent to the heart failure baseline to enable
survival. Sensing is carried out by monitoring the pump mean speed and switching to a
constant speed reference point when the mean pump speed falls below the threshold for
long periods of time.
The lack of circulation to the lungs resulting from ventricular fibrillation and
asystole will cause patient death if not reversed quickly, even if the LVAD was pumping.
By ensuring that the lack of pump flow does not cause mortality, the safe mode keeps the
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pump viable by preventing thrombosis in the event the patient is resuscitated. The
performance of the proposed controller may diminish in the event of pump thrombosis
and inflow/outflow cannula kinking which affects the dynamics of the LVAD and change
the measured ∆RPM. It may be necessary for a clinician to adjust the RPM setpoint for
physiologic control and suction prevention in these extenuating circumstances.
The lumped parameter circulatory system model used in this study has several
limitations. Firstly, it assumes that blood is a Newtonian fluid, the heart valves are ideal
valves (i.e., no regurgitation, no pressure drop, and instant closure), and gravitational
effects are not accounted for. Additionally, baroreceptor and neurohumoral responses
cannot be replicated by the model. On the other hand, this previously validated
circulatory system model demonstrated the feasibility of the 𝛥𝑅𝑃𝑀 control algorithm for
physiologic perfusion and suction prevention. A mock flow loop and large animal studies
are required to validate the controller's performance and demonstrate its long-term safety,
efficacy, and reliability.
Lastly, the proposed 𝛥𝑅𝑃𝑀 algorithm was able to augment arterial pulse pressure
from ~98/92 to 115/85 at rest, at a frequency of ~10 beats per minute. The exact pulse
flow modulation strategy that is able to alleviate adverse events associated with
diminished pulsatility is still unknown. The vascular endothelium is in constant contact
with blood flow and responds to alterations in blood flow hemodynamics such as shear
stress, pulse pressure, and stretch. Moreover, arterial vascular wall contains smooth
muscle cells that regulate the vascular tone. While in this chapter, the advantages of
𝛥𝑅𝑃𝑀 control algorithm was demonstrated, and it was extended to safely augment
vascular pulsatility. However, without knowing the arterial flow waveform that can
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potentially normalize the vascular phenotype, it remains less used. In the following
chapter, an in-vitro culture model of the arterial blood vessel is proposed as a platform for
investigating and optimizing pulse flow modulation strategies to improve adverse events
associated with CFLVADs’ diminished pulsatility.

2.9 Conclusion
A sensorless control algorithm was developed for continuous flow ventricular assist
device to provide physiologic perfusion, prevent ventricular suction and augment arterial
pulsatility through pulse flow modulation. The proposed algorithm requires only the
measurement of intrinsic pump speed, eliminating the need for implantable sensors or
model-based estimation methods. The in-silico results demonstrated feasibility and
robustness of the proposed sensorless control algorithm over a wide range of clinical test
conditions and measurement noise levels. The proposed control algorithm does not
require any pump design modifications and may be readily incorporated into existing
blood pumps. Control based on native reserve contractility showed its versatility in being
extended to augment arterial pulsatility in addition to extracting different measures of
pulsatility such as a suction index from noisy pump speed signal.
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CHAPTER 3: ASSESSMENT OF PULSE FLOW
MODULATION USING AN INVITRO MODEL OF THE
ARTERIAL WALL
3
3.1 Effects of Flow Hemodynamics on ECs and SMCs
The blood vessel is an active multilayered barrier that consists of the inner endothelial
cells (ECs), which are enveloped by smooth muscle cells (SMCs). EC layer is in constant
contact with the inner blood flow and thus reacts to mechanical forces generated by the
pulsatile flow through the vessel lumen. ECs communicate stimulations such as shear
stresses, pressure, and stretch forces by the release of bioactive molecules to promote or
repress vasodilation, inflammation, tissue remodeling, proliferation, apoptosis and cell
migration (e.g. [18-20]). Hence, pathological flow conditions can trigger adverse
adaptation and remodeling by the vasculature. EC adaptation to the mechanical
environment has been previously examined in literature by using in-vitro cell cultures of
ECs usually within a parallel flow plate in the absence of SMCs.
In vivo, however, ECs are not isolated and can actively communicate these changes
with surrounding interstitium and SMCs. Indeed, some growth factors are secreted by
both EC and SMC and can act on both cell lines such as transferring growth factor (TGFβ) and platelet derived growth factor (PDGF) [205]. EC and SMC can communicate by
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cell-cell contact as well as through soluble components. Few in-vitro models
incorporated cocultures (e.g., [206-210]). Typically, ECs and SMCs are either cultured on
both sides of a porous membrane, directly cultured over each other with ECs on top, or
have SMCs embedded in a collagen matrix. However, these studies do not accurately
replicate the physiologic mechanical environment and have mostly shown the response of
EC-SMC coculture to singular mechanical stimulation namely either stretch, shear stress,
or cyclic frequency.
In-vitro study of vascular alterations during CFLVAD support is a multifactorial
problem involving pulse rate, stretch, and shear stress effects. The effect of shear stress
on endothelial cells (EC) morphology has been shown in previous studies [211-213]
where the cells are elongated, larger in size and oriented with the direction of the flow in
areas of high shear stress, while more polygonal-shaped and randomly oriented
phenotypes can be seen in areas of low shear stress areas such as bifurcations. However,
the cellular level changes go beyond morphology; low shear stresses have been related to
increased oxidative stress, changes in cellular growth rate, higher expression of
proinflammatory adhesion molecules and the production of biologically active molecules
[18, 19]. Elevated continuous and pulsatile shear stresses, on the other hand, can cause
vasodilation by upregulating nitric oxide synthase, and super oxide dismutase which can
induce endothelial dysfunction[214, 215]. Moreover, chronic goats studies using
CFLVADs have shown reduced vasoconstrictive response to norepinephrine, thinner
vessel walls, and smooth muscle cell (SMC) atrophy [216]. The alignment of EC and
smooth muscle cells (SMCs) is also affected by frequency of the cyclic stretch. The
cyclic stretch of SMCs cultured on a flexible membrane significantly increased the
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portion of cells aligned in the longitudinal direction (75°-90°) with the radial direction
[217]. The study also showed that this frequency-dependent alignment could be regulated
through Integrin-ß1, p38 MAPK, and the actin filament polymerization system.

3.2 Effects of CFLVAD flow on the vasculature
CFLVADs have emerged as a standard therapy for end stage heart failure due to a
shortage of donor organs. Clinically, CFLVADs are predominantly used over pulsatile
flow devices, because of their higher reliability, energy efficiency, smaller size and
simpler implantation procedure. [218] However, diminished pulsatility in long-term
CFLVAD support has been associated with abnormal physiologic profile of myocardial
and vascular energy utilization, gastrointestinal (GI) bleeding, hemorrhagic strokes,
arteriovenous malformations (AVMs), valve fusion, and end organ failure. [148, 149]
The formation of AVMs indicates an increase in vasculogenic activity, and the
endothelial dysfunction associated with diminished pulsatility is thought to be a result of
activation of Nrf-2 mediated antioxidant response and production of inflammatory and
proangiogenic cytokines. [219] The bleeding events are associated with Von Willebrand
Factor (we) degradation due to high shear stresses, mostly occurring at the pump. [220]
Interestingly, this takes place in both PFLVADs and CFLVADs. However, low shear
stresses during CFLVAD support and the subsequent low vow production thereof has
been attributed to the higher rates of GI bleeding under CFLVAD support compared to
PFLVAD support. [220, 221]

3.3 State of In-vitro Vascular Modeling from Literature
Large animal models fail to capture many of the complications observed in CFLVAD
patients due to anatomical and physiological differences – animals are usually healthy
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and are young, while VAD patients are typically older with chronic disease. [222]
Clinical studies are highly relevant but are not tightly controlled as patients typically have
confounding factors. Thus, study of cellular level vascular adaptations in both EC and
SMC in a physiologic cell culture model is ideal as it is highly controlled and largely
devoid of confounding factors. Given limitations with large animal models,
physiologically relevant in-vitro models of the human arteries may provide the best
opportunity to evaluate the effects of diminished pulsatility as seen in patients with
CFLVADs
The conditions used in most in-vitro systems poorly represented the physiologic
conditions in the arterial system where either continuous or sinusoidal flow waveforms
were used, and mechanical cyclic stretch was either not incorporated or introduced
uniaxially to the membrane upon which the cells were cultured [205, 214, 223]. These
conditions fail to replicate the flow shear stresses and pressure-related deflection of blood
vessels. In vivo, EC are not isolated and can actively communicate these changes with
surrounding interstitium and smooth muscle cells (SMC). Some growth factors are
secreted by both EC and SMC and can act on both cell lines such as transferring growth
factor (TGF-β) and platelet derived growth factor (PDGF) [205]. EC and SMC can
communicate by cell-cell contact as well as through soluble components. However, fewer
invitro models incorporated cocultures (e.g., [206-210]). Typically, ECs and SMCs are
either cultured on both sides of a porous membrane, directly cultured over each other
with ECs on top, or have SMCs embedded in a collagen matrix. However, these studies
lacked some aspect of the physiologic mechanical environment and have mostly shown
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the response of EC-SMC coculture to singular mechanical stimulation namely either
stretch, shear stress, or cyclic frequency.
In literature, few groups were able to achieve accurate replication of physiologic
flow exposure conditions. Table 3-1 and Figure 3-1 provide a summary of some of the
notable coculture models. Robert et al [208] used human vascular cells to engineer a 3D
artery model mimicking the structural as well as functional characteristics of the native
artery. While, their model is realistic, the pulsatile flow exposure was not physiologic,
and the setup and seeding are lengthy and complex which may hinder its future use. Zhou
et al [224] cultured ECs and SMCs on both sides of a porous membrane in a transwell
cell culture insert. Their coculture model however used sinusoidal flow to simulate cyclic
shear stress with a minimum shear stress > 0 dyne/ cm2. Van Engeland et al. [209]
created a microfluidic arterial model composed of a suspended porous membrane
separating a monolayer of SMC and EC. The flow was steady and laminar and cyclic
stretch was introduced directly to the membrane itself. While the model includes two
modes of mechanical stimulation, the flow is continuous, and the shear stress is almost
constant with a very low Womersley number. Further, the stretch is applied uniaxially
and the membrane deflection is minimum and cannot mimic the distention geometry of in
vivo artery. Elliott et al [206] used an EC monolayer culture over a collagen-SMC
construct and was subjected to pulsatile flow under physiologically relevant shear
stresses. However, the coculture was not subjected to cyclic strain and was seeded over a
stiff glass slide.
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Figure 3-1 Four most relevant in-vitro vascular models from Literature. A- adapted from Robert
et al. [208] The system consists of a 3D tubular scaffold that is cultured with ECs and fibroblasts.
Flow is introduced through the lumen of the tube and circulated using a peristaltic pump, BCulture system developed by Zhou et al. [224] ECs and SMCs are cultured on both sides of a
porous membrane and constant flow is introduced to the bottom of the plate where the ECs are
cultured. C- system developed by Van Engeland et al. [209] The study used a microfluidic vessel
wall on a chip. The device consisted of two vacuum chambers and a cell culture chamber. ECs
and SMCs were cultured on both sides of a porous PDMS membrane with flow running on the
upper and lower culture chamber. The vacuum chambers were used to cyclically stretch the
porous membrane, D- Adapted from Elliott et al. [206] A Pulsatile flow loop was externally
connected to a stiff, glass micro culture chamber. ECs and SMCs were culture on both sides of
porous membrane resting on the glass bottom and subjected pulsatile flow.

Robert et al
[208]

Description
Biodegradable 3D tubular
scaffold seeded with ECs and
fibroblasts
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Limitations
Non-physiologic flow
pulsatility, no flow or pressure
measurements, and no SMCs
seeding.

Zhou et al [224]

Van Engeland
et al [209]

Elliott et al
[206]

ECs and SMCs cultured on both
sides of a porous membrane in a
parallel plate flow subjected to
pulsatile or steady flow
ECs and SMCs cultured on both
sides of a porous membrane;
cyclic stretch introduced
uniaxially to the membrane
ECs and SMCs culture on both
sides of a porous membrane
subjected to a pulsatile flow loop.

Non-physiologic sinusoidal
flow and pressures, stiff glass
bottom and stretch.
Very low flow pulsatility, nonphysiologic stretch and
pressures.
Cultured on a stiff glass slide,
thus no stretch, no pressure
measurement.

Table 3-1 Comparison of the most relevant coculture vascular models from literature with
their description and limitations.

3.4 Study goal and hypothesis:
While flow modulation has been proposed as an alternative to true pulsatile flow,
validation of these strategies is complicated. Physical aspects like Pulse Pressure (PP),
Energy Equivalent Pressure (EEP), and Surplus Hemodynamic Energy (SHE) can be
validated using computer simulations or mock flow loops. However, evaluation of the
effect of artificial pulsatility on cells, tissues, and organs that make up the circulatory
system require cellular or animal studies. There are obvious limitations to current in-vitro
models of the arteries that pose limitations on our ability to study the effects of CFLVAD
flow on the vasculature. [225] In order to study these strategies preclinically, the effects
of each element of the pulsatile waveform needs to be assessed in a physiologically
relevant model.
We have previously developed an endothelial cell culture model that can better
replicate physiological mechanical environment of the vasculature [226, 227]. In the
present study, we expand on this model and develop an endothelial-smooth muscle cell
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coculture model to evaluate the effects of flow pulsatility as well as pulsatile frequency
on ECs and SMCs organization, size, and alignment.

3.5 Study Hypothesis
We hypothesize that artificial pulse frequency, stretch, and shear stresses in the
arterial vasculature all play an important role in the regulation of vascular response for
both ECs and SMCs and may be target parameters for the optimization of pulsatile
control strategies for both PFLVADs and CFLVADs.

3.6 EC-SMC Coculture Model Components:
System Layout
With the clear shortcomings of in-vitro vascular models discussed, we developed a
direct Endothelial Cell- Smooth Muscle Cell coculture model. The platform shown in
Figure 3-2 (A) consists of a PDMS rectangular channel with a suspended flexible

polymeric 500μm thin membrane of elasticity matching that of human aorta (Youngs
Modulus~ 500 kPa). Under pressurized flow, the membrane will distend to create a
segment of a blood vessel. Human aortic endothelial cells (ECs) were cocultured with
SMC on the polymeric film. A pulsatile flow pump (Model 1407, Harvard Apparatus,
Holliston, MA) with adjustable frequency and stroke volume is used to produce pulsatile
flow. One-way valves were used to ensure unidirectional flow. A tunable flow resistance
mimics the systemic vascular resistance, and a tunable compliance element represents
arterial compliance. Complete cell culture media was used as the working fluid during
experimentation. The compliance element, flow resistance, pump stroke volume, and
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pulsatile pump frequency can be adjusted to create the desired flow conditions as
previously discussed in [226, 228].

Figure 3-2 A- coculture model loop setup showing the external flow loop connected to
the flow channel inlet and outlet to generate tunable flow and pressure waveforms. The
magnified view shows details of the PDMS Coculture channel connected to the inlet and
outlet of the miniaturized mock flow loop, B- Schematic representation of the Coculture
model.
Experimental Design
The effects of pulsatility and pulsatile frequency on EC and SMC were evaluated
during: (1) normal pulsatile flow (120/80 pulse pressure and 60 bpm), (2) low cyclic
frequency (115/80 pulse pressure and 30 bpm) and (3) diminished pulsatility during
CFLVAD support (98/92 pulse pressure and 60 bpm). ECs and SMCs were directly
cultured on a flexible, thin membrane where it was subjected to the three flow regimes.
The flow conditions were modulated so that the mean arterial pressure and the average
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flowrates in all three cases were 95 ± 1 mmHg and 10.1 ± 0.5 ml/min. This ensured that
any effects seen on cell size and morphology are due to pulse frequency, and
flow/pressure pulse modulations. Cell morphology was assessed using fluorescent
microscopy and shear stresses were calculated by simulating the flow chamber using
CFD software under different conditions. Details are presented next.

EC-SMC Co-culture Chamber Fabrication
First, the PDMS flow channel was created using standard soft lithography as
described previously in [226] and had a height, width, and length 0.3 mm, 5 mm, and 25
mm, respectively with an inlet and outlet ports on top. The final cell culture chamber was
fabricated by irreversibly bonding a thin membrane of PDMS (500 µm) to a rectangular
PDMS chamber using oxygen plasma bonding. Inlet and outlet ports were connected
through the top holes to create a continuous recirculation of the culture medium.
Cell Culture
Human Aortic Smooth Muscle Cells (HASMCs) and Human Aortic Endothelial
Cells (HAECs) (ATCC, Manassas, VA, and Invitrogen, Carlsbad, CA) were initially
cultured and maintained according to the supplier’s instructions in standard tissue culture
flasks. Prior to seeding within the cell culture chamber in the ECCM, the surface of the
cell culture chamber was treated with 50 mg/mL of a solution containing a mixture of
attachment factor, gelatin, and fibronectin for 12 h at 4 °C and for 1 hr. at 37 °C to
promote cell adhesion. Cells were stained with 15mM cell tracker (Invitrogen, Carlsbad,
CA) blue for SMCs, and red for HAECs. The cell culture chamber was first washed with
culture medium (M-200, with the addition of low serum growth supplement, Invitrogen,
Carlsbad, CA). SMCs were seeded at a density of 5 × 105 cells/mL. Cells were
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incubated at 37 ˚C in a humidified atmosphere containing 5% (v/v) CO2. After 48 hours,
the culture chamber was washed and coated with 50 mg/mL fibronectin for 3 hours at 37
°C and was washed with cell culture medium and seeded HAECs at a density of 5 × 105
cells/mL, cells were allowed to attach and spread for 4 hours, after that the medium was
replaced and maintained in culture until they reached confluence. Once they reached
confluence, they were assembled in the flow loop and subject to different pulsatile and
flow conditions (24 hours) to analyze the cell growth and alignment under fluorescent
microscope. To do that, SMC and HAEC were stained with cell tracker red and blue (Thermo
Fisher Scientific, Waltham, MA), to achieve live imaging and visualize the cell growth and
alignment. Average cell size was calculated on 10 cells for each condition using image J software
(NIH, Maryland, USA).

Pressure and flow measurement
Pressure and flow measurements were accomplished using inline pressure and
flow sensors (Millar Instruments, TX and Transonic Inc., NY). Laser-induced
fluorescence (LIF) was used to track the membrane deflection under applied pressure
using an imaging setup also described in [226]. Shear stress measurements utilized the
flow data in conjunction with change in channel cross-section following application of
pressure.
Shear Stress Calculation
Formulae developed to calculate shear stress from flow conditions are based on a
rigid rectangular flow chamber geometry. To establish a more accurate numerical
calculation of the shear stress on the flexible membrane for each flow condition, a threedimensional Computational Fluid Dynamic (CFD) simulation of the flow chamber was
performed using finite element analysis (ANSYS-CFX, Canonsburg, PA). The membrane
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deflection was calculated using LIF under different fluid pressures. Figure 3-3 shows a
plot of the membrane deflection at the centerline of the membrane versus the flow
chamber pressure. This relation was used to calculate the membrane’s new curvature at
different pressures during the CFD simulation. The dimensions of the flow chamber
ensure a predominantly circumferential strain in the membrane except near the inlet and
outlet. For CFD simulation and to negate entrance effects, only the fully developed
section of the channel was considered for the shear stress calculation. The hydrodynamic
entrance length was calculated as
𝐿 = 0.05𝑅𝑒 𝐷ℎ

(9)

Where 𝐿 is the entrance length, 𝑅𝑒 , is Reynolds number, and 𝐷ℎ is the hydraulic
diameter. The CFD solver uses the three-dimensional conservation of mass and
momentum equation, coupled with a turbulence model solver. 𝑘– 𝜔 turbulence model
was used for the Reynolds Averaged Navier Stokes equation (𝑅𝐴𝑁𝑆) to provide
mathematical closure to the equations of motion. 14 discrete flow points were simulated
for each pulsatile mode. The flow channel dimensions were updated using the relation
from Figure 3-3 for each flow point.
Adequate meshing was achieved using ANSYS built in mapped mesh and sweep
method over the length of the flow chamber thus controlling the number of elements in
the width direction and along the flow direction. A mesh independence analysis was
carried out to obtain a mesh that provides accuracy with minimum computational effort.
The mesh element size was changed in all three axes until an acceptable stability of
solution was obtained at 157500 elements.
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Statistical Analysis and data processing
Data was collected using PowerLab 30 (ADInstruments, Dunedin, New Zealand).
Calculations, filtering, and analysis were done using MATLAB (MathWorks, Natick, MA,
USA). One Way ANOVA in Minitab software (Minitab LLC, State College, PA) was used
to compare the cell size among different experimental group with a confidence interval of
95%.
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Figure 3-3 PDMS membrane deflection obtained as a function of flow channel pressure
using Laser Induced Fluorescence imaging of the culture membrane.

3.7 Results
Emulation of different flow conditions within the culture chamber
The cell culture chamber had a rectangular shape with 0.3 mm height, 5 mm width
and 25 mm length. Normal flow pressures were 120/80 mmHg (max/min) and at a
frequency of 60 ± 5 bpm, . CFLVAD flow replication pressures were 98/92 at a frequency
of 60 ± 5 beats per minute. CFLVAD flow modulation condition pressures were 115/80
mmHg at a frequency of 30 ± 5 bpm as shown in Figure 3-4. All three pressure and flowrate
waveforms were adjusted to maintain a mean pressure of 95 ± 1 mmHg and a mean flowrate
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of 10.1 ± 0.5 ml/min. Mean arterial pressure (MAP), Energy Equivalent Pressure (EEP),
and Surplus Hemodynamic Energy (SHE) were calculated from the flow regimes as shown
in Table 3-2.
Normal
pulsatile
flow

Diminished Low cyclic
pulsatility
frequency

Mean Arterial
95 ± 1
95 ± 1
pressure
95 ± 1 mmHg
mmHg
mmHg
(mmHg)
Mean flow rate
10.1 ± 0.5 10.1 ± 0.5
10.1 ± 0.5
(mL/min)
Energy Equivalent
Pressure
100±2
95±2
98±2
(mmHg)
Surplus
Hemodynamic
6828±158 153.8±25
5156±149
Energy
(erg/cm3)
Table 3-2 Calculated pulsatility measurements for each condition
studied. The mean flow rate and mean arterial pressure was
maintained constant for all three conditions. SHE was lowest in
diminished pulsatility conditions, while low cyclic frequency
showed close to normal, SHE.

Estimation of shear stress inside the coculture chamber
Shear stress distribution confirmed a laminar flow with maximum shear near the
central axis of the membrane and minimum shear stresses towards the periphery, as shown
in Figure 3-5. To confirm the accuracy of the simulation results, shear stresses were also
calculated analytically for the three conditions using the approximate analytical relation:
τ = 𝛼⁄ ×
√2

6𝑄𝜇⁄
ℎ2 𝑤

(10)
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Where 𝑄 is the volume flow rate, h and w the height and width of the channel
respectively. α is the Wormsley parameter which arises in the solution of Navier Stokes

Normal

Diminished pulsatility

Low cyclic Frequency

Figure 3-4 Pressure, flowrate, and estimated shear stress waveforms are shown
for each condition. The reduced pulse pressure and peak flowrate and shear stress
is clearly seen with diminished pulsatility. The average flowrate and average
shear stresses were kept equivalent between all conditions
equations for pulsatile flow and was determined to evaluate the ratio of pulsatile
flow frequency to viscous effect using the following equation:
1
2𝜋𝑓𝜌
𝛼 = 𝐷ℎ √
2
𝜇

(11)

where 𝜌 is the culture media density, 𝑓 is the flow pulse frequency, 𝐷ℎ is the
hydraulic diameter, and 𝜇 is the culture media viscosity. The average shear stress for all
conditions was within 4.2 ± 0.5 𝑑𝑦𝑛𝑒/𝑐𝑚2. The resulting flow waveforms, pressure
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waveforms, simulated shear stress, and analytically approximated shear stress are shown
in Figure 3-4. The shear stress varied between −0.12 and 17.09 𝑑𝑦𝑛𝑒/𝑐𝑚2 for normal
flow condition, 3.39 and 6.94 𝑑𝑦𝑛𝑒/𝑐𝑚2 for diminished pulsatility condition and
−2 𝑎𝑛𝑑 19.06 𝑑𝑦𝑛𝑒/𝑐𝑚2 for CFLVAD flow modulation condition.

Diminished pulsatility

Low cyclic frequency

Point 3

Point 2

Point 1

Normal

Figure 3-5 Simulated wall shear stress is shown at 3 distinct time points on a
representative flow pulse for each condition, as shown in the top panel. The peak shear
stress is lowest with diminished pulsatility condition, while the peak shear stress is
slightly higher for low cyclic frequency (30 bpm, 2 seconds cycle time) compared to
normal pulsatile (60 bpm, 1 second cycle time).
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Assessment of HAEC and SMC morphology and alignment
Fluorescent probing with cell tracker blue and cell tracker red for SMC and
HAEC respectively is shown in Figure 3-6. Microscopic analysis revealed change in cell
size between normal pulsatile flow, low frequency flow modulation support, and
diminished pulsatility with CFLVAD support (Fig.6). Compared to normal pulsatile
conditions, diminished pulsatility during CFLVAD support (CFLVAD flow replication)
showed a statistically significant reduction in HAEC size (p<0.01). Low frequency flow
modulation support did not lead to a statistically significant reduction in EC cell size,
suggesting that the decreased frequency with flow modulation had no to minimal effect
on EC size. Statistically significant differences in SMC size were observed during low
frequency flow modulation (31%, p<0.01) and diminished pulsatility with CFLVAD
support flow (55%, p<0.01).

86

Figure 3-6 Live imaging of ECs and SMCs using fluorescent staining. The aligned
morphology of ECs and SMCs in seen in with low cyclic frequency and normal pulsatility
conditions, while a disrupted alignment and smaller cell size is seen in diminished
pulsatility condition.
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Figure 3-7 Cell size assessment of simulated conditions. ECs and SMCs size were
significantly reduced with diminished pulsatility. Low cyclic frequency maintained
normal EC size (p=0.07) while SMC size was significantly reduced (* p < 0.001).

3.8 Discussion
EC-SMC coculture model as a platform to study effects of vascular
pulsatility
Experimental models of blood vessels are desirable for studying vascular
physiology and pathophysiology. The ability to adequately model the arterial wall can
provide new insights into vascular function, elucidate details molecular signaling
pathways, and predict drug response. Historically, in-vivo small, and large animal models
have been instrumental in developing of our understanding of vascular biology. However,
the differences between human and animal vascular biology limit the interpretability of
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animal experiments and threatens the translatability of such models’ response to drugs
and therapies.
Here, we developed a direct EC-SMC coculture model of the arterial wall that is
able to replicate the hemodynamics of large arteries include pressures, shear stress, and
stretch. The use of both ECs and SMCs is critical for accurate for vascular modeling.
Blood vessels are complex in nature. The inner endothelial wall is surrounded by smooth
muscles and connective tissue. The surrounding biomechanical environment, that is shear
stress, mechanical strain, pulse flow, and pulse frequency all play critical roles in the
maintenance of ECs and SMC morphology, phenotype, and function. [52, 229, 230]
Therefore, the accurate replication of this mechanical environment is indispensable when
building in-vitro models for human vasculature. Our results demonstrate the
physiological relevance of the EC-SMC co-culture model to replicate hemodynamic
conditions within the vasculature. The arterial pressure was 120/80 mmHg for normal
pulsatile flow, 98/92 mmHg with CFVAD support, and 115/80 mmHg with flow
modulation, which correspond to clinically observed values of systolic and diastolic
arterial pressures. [231] The mean pressure and mean flowrate were maintained at 95 ± 1
mmHg and 10.1 ± 0.5 ml/min respectively for all groups. The flow was scaled down in
the cell culture model loop to ensure physiologic values of shear stress in the cell culture
model (average shear stress = 4.2 ± 0.5 𝑑𝑦𝑛𝑒/𝑐𝑚2 ) [232]. The peak shear stresses are
higher (15 ± 2 𝑑𝑦𝑛𝑒/𝑐𝑚2 ) in both normal pulsatile flow and flow modulation (low
cyclic frequency) conditions. In this setup, the coculture culture model represents a 5
mm circumferential section of the aortic wall (~ 1/5th of a human aorta) and accurately
mimics SHE on the simulated vascular section ~1/5th physiological values).
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Importantly, the SHE is diminished by ~98% with CFLVAD support when
compared to normal pulsatile flow, which is in agreement with clinical results, [233].
Flow modulation, even at a lower frequency, significantly augments SHE. Importantly,
the EC-SMC co-culture model has a confluent layer of endothelial cells between the
SMC and fluid, which enables the communication and shared signaling pathways
between ECs and SMCs that contribute towards the development, maintenance,
regulation, and remodeling of the vasculature under normal and pathological conditions.
Limitations to pulse flow modulation strategies
Clinical complications associated with CFLVADs have renewed efforts to attain
pulsatile flow with CFLVADs. Rather than reverting to pulsatile flow VADs that are
bulky, less efficient and less reliable; recent efforts have focused on generating pulsatility
using CFVADs via an approach called ‘flow modulation’ (i.e.) rapid changes in pump
speed (HeartWare HVAD or Heartmate III).[234, 235] Flow modulation can be
accomplished in two ways: (1) Synchronous Flow Modulation: where changes in pump
speed are accomplished in synchrony with native myocardial contractions.[236-238] The
only variable that can be modulated is the pulse pressure. Unlike the native ventricle,
which can generate peak flows of 30-40 L/min, CFLVADs are limited to peak flow rates
of approximately 10 L/min, which limits the pulse pressure that can be generated with
synchronous flow modulation to < 20 mmHg. Significantly, long-term sensors are
necessary to monitor native heart rate to detect onset of ventricular systole to synchronize
the frequency of pump speed changes, and (2) Asynchronous Flow Modulation: where
changes in pump speed are accomplished independent of the native heart rate.[239, 240]
Both pulse pressure and frequency can be modulated to achieve desired levels of
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pulsatility. In terms of implementation, asynchronous flow modulation is simpler, as
long-term sensors are not required to synchronize to the native heart and multiple
variables (pulse pressure and frequency) can be changed. Asynchronous modulation at
lower VAD flow modulation rates (≤ 30 bpm) can generate near physiological pulse
pressures (~35-40 mmHg) even with peak CFLVAD flow rates limited to 10 L/min.
Effects of low cyclical flow pulsatility on EC and SMC size and morphology
This study demonstrated that diminished pulsatility, characteristic of CFLVAD
support results in significant morphological changes of both EC and SMC, resulting in
cell size reduction compared to normal pulsatility. This reaffirms the important role of
pulsatility in maintaining normal vascular function and tone. In our study flow
modulation that restored pulsatility to 35 mmHg or higher, even at much lower
frequencies compared to normal cardiac rhythm, was able to substantially normalize EC
morphology, as evidenced by improved cellular alignment and maintenance of EC cell
size. Changes in pulsatility primarily impact arterial vessels, where ECs are the primary
mechano-transducers. Non-surgical bleeding events occur downstream of large vessels in
arterioles, venules, and capillaries. While there is no established causal relationship tying
pro- inflammatory/pro-angiogenic factors in large vessels to non-surgical bleeds, loss of
pulsatility-mediated endothelial dysfunction and cytokine production is suspected to be
the cause of downstream microvascular dysfunction that leads to non-surgical bleeds.
This is based on published reports that found angiopoietin-2 (Angpt-2) levels to be
significantly higher in CFLVAD patients with non-surgical bleeding events than in
patients with heart failure or orthotropic heart transplants.[241-243] Additionally, various
inflammatory cytokines including IL-6, IL-8, TNFα and IL-1β were also found to be
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acutely elevated following CFLVAD implantation with levels of IL-6 and IL-8 remaining
elevated even after 6 months of implantation.[244] Review of literature associated with
AVMs and bleeding events in general suggests elevated levels of cytokines associated
with inflammation, vascular instability and vascular permeability including IL-1β, IL-6,
IL-8, TNF-α, HIF-1, NF-kB, VEGF, MMP-9 and decreased TIMP levels.[245-252].
Furthermore, ECs from older individuals under CF-VAD flow results in elevated levels
of pro-inflammatory (IL-8, IL-12, IL-15, MDC) and pro-angiogenic signaling (VEGF,
BMP-9, IL-8, FGF-1, ET-1, Angpt-2, HB-EGF, HGF).[253] Thus, indicate the
normalization of pulsatility even at a lower frequency can substantially minimize
endothelial dysfunction and concomitant adverse events.
Pulsatile modulation in CFLVAD normalized EC, but not SMC size
Indeed, in our study low cyclical frequency flow modulation approach that
generated 35 mmHg of pulse pressure enhanced the cell size of SMC compared to
diminished pulsatility. However, SMC cell size was still significantly lower compared to
normal pulse pressure and frequency condition. However, it should be noted that SMCs
showed a significant improvement with low cyclical frequency over diminished
pulsatility. Previously, Scott et al [254] demonstrated that EC-SMC coculture in high
pulsatility flow (high pulse magnitude) increased SMC size and expression of contractile
proteins, smooth muscle actin (SMA) and smooth muscle myosin heavy chains (SMMHC) while in the absence of ECs, high levels of pulsatility demonstrated no significant
change in cell size, and a reduced regulation of SMA and SM-MHC. Compared to our
experiments, their model did not incorporate any cyclic strain. In the light of the present
results, this may suggest that SMCs are more responsive to cyclic stretching than flow
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shear forces and that in the absence of stretch, the changes in SMC shape and size may
mostly be communicated through EC signaling. Previous studies [231] have
demonstrated a significant increase in vascular impedance due to diminished pulsatility
with CFLVAD. Given the observed change in SMC morphology with diminished
pulsatility, our results indicate that while SMC morphology improves with asynchronous
pulse modulation of CFLVAD, some level of derangement of vascular tone in patients
may likely exist even with asynchronous pulse modulation support.
Although it is premature to base interpretations solely on cell morphology, these
results suggest that there may exist a combination of pulse flow and pulse frequencies
which can maintains both ECs and SMCs function and morphology. Future work will use
the EC-SMC co-culture platform to do a more in-depth investigation of more relevant
biomarkers such as SMC contractile protein expression, oxidative stress, angiogenesis,
and inflammation markers to guide further optimization of pulse flow modulation.

3.9 Limitations
HAECs and HASMCs were obtained from healthy cell lines and are not
representative of the altered phenotype present in heart failure patients. This was
mitigated by keeping the cell culture in altered physiologic condition for at least 24
hours. The co-culture model does not incorporate the paracrine signaling that is present
in-vivo but enables study of multiple mechanical loading conditions in a tightly controlled
environment. Only one flow modulation strategy was tested, but the cell culture model is
capable of simulating any flow modulation protocol that is physiologically feasible. The
CFD simulation done to estimate the shear stress inside the flow chamber used 14
discrete time points during which the flow, pressure, and membrane shape were used to
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estimate the shear stress at the wall. This method would not incorporate potential timedependent effects of the pressure and flow on the culture membrane. However, the CFD
values were in good agreement with theoretical values. The CFD studies indicated
abnormal shear values in the entrance region, which may affect the EC and SMCs in that
region. Cells from the entrance region were not used for analysis in this study to mitigate
this concern.

3.10 Conclusion
In this study, we developed an endothelial-smooth muscle direct coculture model
for human vasculature developed. The coculture was used to test the relative effects of
diminished pulsatility and frequency modulation on cellular organization and size. As the
need for robust in-vitro testing platforms grows, this novel coculture model holds the
potential to be used for different types of drugs and device development and testing. The
device supports physiological flow and strain and prolonged EC and SMC coculture with
physiological cellular phenotypes, organization, and interactions. By using the developed
system, we demonstrated that while low frequency pulse flow modulation can potentially
normalize ECs morphology, it may not be adequate to prevent SMC atrophy.
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CHAPTER 4: DEVELOPMENT OF A CARDIAC TISSUE
CULTURE MODEL TO EMULATE THE PHYSIOLOGICAL
CARDIAC ENVIRONMENT 3
4
4.1 Introduction
There has been an ongoing interest in the development of efficient and effective
drugs and therapies for the diseased heart. However, the complexity of the human heart
makes accurate prediction of drug effects difficult. Moreover, successful translational
research requires preclinical models at an adequate level of complexity to assess the
impact of treatments on bio-targets as well as any collateral effects they may have. Small
and large animal models are most commonly used for cardiac research. However, the
anatomical and physiological interspecies differences are not trivial, including differences
in thrombogenicity, heart rate, electrophysiology, and heart tissue composition. [57, 58]
Alternatively, in-vitro cellular models of the myocardium are readily available,
and their relative simplicity facilitates clear interpretation of data. [89, 255] Indeed, such
models have been instrumental in drug development as well as developing our
understanding of the cellular myocardial environment. Nevertheless, current in-vitro
myocardial models suffer serious limitations. Isolation of primary cardiomyocyte

Parts of the work in this chapter has been published in [1]
M. H. Meki, J. M. Miller, and T. M. A.
Mohamed, "Heart Slices to Model Cardiac Physiology," (in English), Frontiers in Pharmacology, Mini
Review vol. 12, no. 23, 2021-February-04 2021, doi: 10.3389/fphar.2021.617922.
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produces low cell yield and will rapidly dedifferentiate in culture within the first 48 hours
in culture, limiting their chronic use. [77] In the absence of proper biomimetic
conditioning, human induced Pluripotent Stem Cell derived Cardiomyocytes (hiPSCCMs) remain fetal and lack many of the adult cardiac phenotype characteristics such as
absent cell-cell coupling, T-tubules, and under-developed sarcoplasmic reticulum. [89,
256]
Thin heart slices have been prepared from human and animal hearts with high
viability and organotypic, multi cell-type structure. [112, 257] Fresh heart slices have
been shown to maintain normal contractile function [120, 257, 258], electrophysiology
[110, 259], calcium homeostasis [120], and response to inotropes. [120, 260] These biofidelic characteristics of heart slices make them an attractive system for disease and drug
research. Historically, however, the usefulness of heart slices has been limited to acute
experiments because of the rapid loss in structural and functional integrity beyond 24 h in
culture. [257] Ou et al. have previously shown that electrical stimulation and abundance
of metabolic substrate can improve the viability and functionality of heart slices in
culture for 6 days.[120] However, by day 10 of culture, the heart slices experienced
significant downregulation of contractile cardiac genes and upregulation of fibrotic
remodeling and inflammatory genes.
By inspection, the lack of mechanical loading and humoral stimulus in culture
may partially explain these observed effects. Multiple studies have shown the plasticity
of heart slices to culture conditions, including changes in preload and afterload at the
functional and transcriptional levels. [258, 261, 262] Thyroid hormones are known to
play a vital role in cardiac development [263], and Triiodothyronine (T3) has been shown

96

previously to improve hiPSC-CMs in culture by increasing contractile force,
mitochondrial activity, and improving calcium handling. [90, 264] Dexamethasone (Dex)
is a potent glucocorticoid that is essential for fetal myofibril assembly and organization.
[265] The combination of T3 and Dex has been shown to improve hiPSC-CMs maturity
in culture and could potentially have the same effects in heart slice culture.

4.2 Study Hypothesis
In order to extend the functional and structural integrity, we hypothesize that the
introduction of mechanical loading similar to physiology, coupled with appropriate
humoral stimulation, can improve the adaptation of heart slices to culture and promote a
more physiological cardiac phenotype. To that end, mere stretching of the tissue
(e.g.,[258]) or uniaxial linear auxotonic loading (e.g., [261]) cannot recreate the normal
physiological mechanical environment necessary for prolonged culture and has shown
evidence of inducing hypertrophic remodeling and downregulation of cardiac genes.
Here, an optimized myocardial slice culture system that incorporates
synchronized electromechanical stimulation in a physiologically mimetic fashion is
introduced. We show that the combination of T3-Dex treatment under physiological
mechanical loading can improve viability, myocardial gene expression, structural
integrity, and decrease fibrotic remodeling.

4.3 Application of synchronized electromechanical stimulation to heart
slices
Multiple groups have shown the plasticity of cardiomyocytes to culture conditions
and that mechanical loading can induce physiological/ pathological adaptation of heart
slices to culture conditions. Therefore, a bioreactor Cardiac Tissue Culture Model
97

(CTCM) that applies synchronized, physiological electromechanical stimulation was
developed. Circular pig heart slices were attached to 7mm rings using surgical histoacryl
glue and placed in the CTCM which can accommodate up to 6 slices to be cultured
together. The goal of CTCM is to mimic the physiological electrical stimulation and
mechanical loading of the native heart, Figure 4-1.

4.4 CTCM operation, design, and characterization
To achieve physiological mechanical loading, CTCM uses a programmable
pneumatic driver to pump air into an air chamber which is topped by a flexible silicone
membrane that separates the air chamber from the culture chamber, as shown in Figure
4-1-A, B. When the membrane distends under pressure, the culture media below the
tissue is displaced and stretches the heart slice, thereby preloading it. As the air chamber
pressure decreases, electrical stimulation takes place and the heart tissue contracts and is
allowed to shorten at a physiological rate. The pneumatic driver was set to 1.2 Hz (72
beats/min) and the systolic time was set to 40% of the cycle, while the diastolic time was
set to 60%, similar to the native heart. The schematic of the culture system is shown in
Figure 4-2. The pneumatic driver was able to accommodate up to 4 devices working at
the same timing and pressure conditions.
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Figure 4-1 A- CTCM exploded view showing different components. The device is
composed of an air chamber and a culture chamber that are separated by a flexible
silicone membrane. The heart slices are glued onto circular rings and placed in the culture
chamber. The bottom membrane will distend under pressure, thereby stretching the
tissue. Graphite electrode pairs provide synchronized electrical field stimulation at 3
V/cm. B- The system setup is shown inside the incubator chamber. The developed system
allows for 4 devices to be simultaneously connected to a single pneumatic driver, with
each device containing up to 6 heart slices.

Figure 4-2 Schematic representation of the Cardiac Tissue Culture System (CTCM).
The pulsatile pneumatic driver pressure line is equipped with a catheter pressure sensor
and is fed into a DAQ which controls the timing of the electrical impulse stimulus.

4.5 Quantification of the heart slice movement using camera tracking
Extensive characterization of CTCM was performed. Firstly, to characterize the
movement of the heart slices within CTCM and confirm that it follows the same
waveform as applied pressure, a custom camera system was built as shown in Figure
4-3-A. Videos were recorded using a DSLR camera (Cannon Rebel T7i, Cannon, Tokyo,
Japan) and Navitar Zoom 7000 18-108mm macro lens, (Navitar, San Francisco, CA).
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Firstly, an open-source software (MUSCLEMOTION, [266]) was used with Image-J to
quantify the movement of the heart slices. As shown in Figure 4-3 -B, the heart slices
followed the expected strain waveform, similar to the input pressure waveform. Here, the
pneumatic driver was set to 72 bpm, or 833.33 ms cycle time. Videos were recorded
every day for 8 cultured heart slices in CTCM for 12 days. Each video trace was
converted to a frame sequence and analyzed using MUSCLEMOTION. The collected
heart slice motion traces were used to quantify the cycle time, relaxation time,
contraction time, contraction rate, and relaxation rate. As shown in Figure 4-3 E, the
cycle time was maintained at 833±32 ms, relaxation time was 509 ± 19 ms, and
contraction time was 333±22 ms. Contraction and relaxation rates were also plotted and
showed a physiological waveform.
To obtain quantitative movement data, frame-by-frame tracking of the peak
movement of the tissue was performed manually using image-J to characterize the heart
slice stretch. To ensure a physiological level of preload stretch, the pneumatic driver was
programmed to a peak pressure of 80mmHg to achieve 25% preload stretch, which
corresponds to a physiological 2.2–2.3 µm sarcomere length [262, 267, 268]. As they
contract during systole, the heart slices are shortened in an auxotonic fashion and follow
a physiological shortening waveform [269] as shown in Figure 4-3-B and Figure 4-4.
The contraction and relaxation velocities were calculated and are plotted in Figure 4-4
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Figure 4-3 A- Camera system used to measure the stretch within each cycle of the heart
slices. B- Assessment of heart slice movement by measuring the dynamic changes in
pixel intensity in MUSCLEMOTION in Image-J. Representative tissue movement is
shown with peak and valley detection that were used to calculate cycle timing and peak
to peak movement. The movement speed was also calculated from the slice movement CMovement speed was calculated from acquired video data showing peak contraction
velocity. D- Representative video frame collected from E- Calculated heart slice timing
using MUSCLEMOTION results showing that 40% of the cycle time was systole and
60% was diastole. The relaxation (diastole), contraction (systole), and cycle times were
calculated for traces of 8 different tissues over 12 days in culture (N=96). F- Close up
representative loading cycle in CTCM showing the heart slice movement and movement
velocity.
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Figure 4-4 Frame by frame analysis of the heart slice stretch over a representative cycle.
The figure shows the calculated percentage stretch for the heart slices. The stretch rate is
shown in orange showing the peak contraction rate and relaxation rate. The tissue is
stretched by 25% during diastole and is electrically stimulated and allowed to contract at
a physiological rate during systole.

4.6 Characterization of the electrical stimulation in CTCM
A custom printed circuit board was designed to interface with an electrical
stimulator (C-PACE EM, IonOptix, Westwood MA). Graphite electrode pairs provided
field stimulation of the heart slice tissue. 2ms Biphasic electrical voltage signal was set to
achieve 3.1 V/cm electric filed intensity at the center of the tissue and was confirmed
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with computational simulation using Finite Element Analysis (FEA), as shown in Figure
4-5.

Figure 4-5 Computational simulation of the electrical field inside the culture chamber,
showing the position of the heart slices within the chamber. The electric field across the
tissue diameter was uniform and did not exceed 3.2 V/cm.

4.7 Estimation of the strain field within the heart slice
As the heart slices are stretched, cardiomyocytes are subjected to circumferential
and radial strain. In the healthy heart the preload strain varies between 15%-27%. [270]
The peak tissue center movement was recorded and was used as reference for the
estimating the strain within the tissue. The simulated strain field within the heart slices at
end of diastole was determined using FEA analysis (ANSYS Mechanical, Canonsburg,
PA). Figure 4-6 shows the central movement out-of-plane of the heart slice tissue and the
resulting radial and circumferential strain along the tissue diameter.
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Figure 4-6 Estimation of strain field within the tissue slice using FEA in ANSYS
Mechanical. A,B- Heart slice deflection under pressure, and C- simulated radial and
circumferential strain in the tissue slice as a function of radial distance across the tissue.

4.8 Experimental Design
To investigate the effects of mechanical loading and T3-Dex treatment on heart
slices, pig heart slices were cultured in CTCM with T3-DexD treatment (MT condition)
and without T3-Dex treatment (MC condition). Additionally, heart slices cultured in
CTCM were compared to static culture controls without T3-Dex treatment (CTRL
condition) and with T3-Dex treatment (TD condition). CTRL and TD were cultured in
transwell plates with nutrient rich medium, oxygenations, and electrical stimulation as
previously described in [62, 271]. All four conditions (CTRL, TD, MC, MT) were
cultured over 12 days and tissue was collected for end point assays and compared to fresh
tissue slices from day 0. A schematic representation of the experimental design is shown
in Figure 4-7.
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Figure 4-7 Schematic representation of the experimental design to evaluate the
performance of CTCM and T3-Dex small molecule treatment. 4 conditions were cultured
using fresh pig heart slices for 12 days: (1) MT, CTCM electromechanically stimulated
tissue with T3-Dex treatment, (2) MC, CTCM electromechanically stimulated tissue
without treatment, (3) TD, unloaded, static tissue treated with T3-Dex treatment, and (4)
CTRL, unloaded, static tissue without treatment.

4.9 Assessment of viability, energy utilization, and structural integrity
in pig heart slices.
To determine the effect of humoral and electromechanical stimulation on heart
slices in 12 days prolonged culture, 6 mm circular sections were punched from each
condition and metabolic activity was assessed using MTT assay as a marker for cell
viability. As shown in Figure 4-8 (A), following 12 days in culture viability did not
significantly decrease in CTCM (MC and MT) conditions and was maintained similar to
fresh tissue (p>0.05). Interestingly, the addition of T3+Dex to transwell culture (TD) did
not significantly improve viability compared to CTRL condition, implying the vital role
of mechanical stimulation in maintenance of heart slice viability.
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Further, to determine if the improvement in viability may be due to alterations in
energy utilization and metabolism, glycolytic flux assay was performed on all four
conditions. Metabolic shift from fatty acid oxidation to glycolysis is a hall mark for
cardiomyocyte dedifferentiation. Immature cardiomyocyte primarily utilize glucose for
ATP production and have underdeveloped mitochondria with few cristae. and shift
towards a fetal phenotype. [1, 272] As shown in Figure 4-8-B, glycolytic flux assay
revealed a significant increase in glucose utilization for energy generation in CTRL
condition compared to day 0 after 12 days in culture. However, MC and MT conditions
showed glycolysis utilization similar to day 0. TD condition caused a higher level of
glycolysis than MC and MT but did not reach statistical significance compared to fresh
tissue (p>0.05).
Next, we investigated if the improvements with humoral and mechanical loading
were reflected on the structural protein level. Mechanical stretch is known to be an
essential stimulus for cardiomyocyte arrangement and contraction. [273, 274] Nonphysiological mechanical loading, or lack thereof, will trigger structural changes of the
sarcomere, contractile machinery, and cellular communication. [275, 276]. To assess
structural integrity of cultured heart slices, immunostaining of cardiac troponin T (cTnT)
and gap junction protein connexin 43 (Cx43) was performed, Figure 4-8- C.
Propagation of the electrical stimulus in the heart is regulated by the gap junctions which
can synchronize action potential progression and contraction. Cx43 is the major connexin
protein expressed in the ventricular myocardium and its normal expression at the gap
junction is essential for coordinated cardiomyocyte electrical activity.[277] At day 12 of
culture, Cx43 was intact and widely localized at the gap junctions in MT condition, with
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normal cell morphology and myofibrillar striation. To characterize the structural integrity
of the imaged heart slices, we developed a deep learning Convolutional Neural Network
(CNN) framework to assess the overall deterioration in tissue structure, organization,
signal intensity, and localization. This AI framework was previously validated and
published in [278]. The automated structural deterioration assessment algorithm outputs
the probability that a given immunofluorescence image is similar to day 0 tissue. Merged
heart slice images fluorescently labeled for DAPI, cTnnT, and Cx43 from each of the 4
conditions were analyzed for their structural similarity to Fresh heart tissue. As shown in
Figure 4-8 (D), T3-Dex treatment significantly improved heart slice structure compared
to CTRL tissue (p<0.001) and was ~48% similar to fresh tissue. Culture in CTCM
appeared to further improve the structural benefits of T3-Dex treatment, where MT
conditions showed the most structural improvement compared to CTRL tissue and
resulted in an overall tissue structure that is ~77% similar to fresh tissue. Interestingly,
while there was a trend towards improvement in MC tissue compared to control, it did
not reach statistical significance (p=0.059) and did not exceed ~30% similarity. These
results provided additional evidence on the synergistic favorable effects of T3-Dex small
molecules and physiological mechanical loading.
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Figure 4-8 A- Tissue viability assessed using MTT assay on day 12 of culture compared
to day 0 tissue. Fresh tissue (D0), N=6, CTRL, N=6, TD, N=3, MC, N=3, MT, N=3. BGlycolytic flux assay after 12 days in culture. D0, N=6, CTRL, N=6, TD, N=6, MC N=6,
MT, N=5. C- Representative immunofluorescence staining image of connexin-43 and
troponin-T on tissue from day 12 in culture. D- Percentage structural similarity of heart
slices after 12 days in culture to fresh heart slices (D0). CTRL, N=6, TD, N=5, MC, N=5,
MT, N=5. One-way analysis of variance (ANOVA) was used to determine if there were
any significant differences between groups. Dots represent individual data points. *,****
groups compared to CTRL * p<0.05, **** p<0.001, # groups compared to D0 p<0.05,
@@@@ groups compared to TD, @@@@ p<0.001, &&&& groups compared to MC,
&&&& p<0.001.
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4.10 Assessment of Fibrosis in heart slices under electromechanical stimulation and
T3-Dex treatment
Immunohistochemical staining for cTnT and Cx43 revealed an improvement in
tissue structure and was based on myofibrillar structure and gap junction protein
localization. Cardiac fibroblasts are the predominant Extra Cellular Matrix (ECM)
producing cells in the heart and are of paramount importance in preserving fibrillar
collagen homeostasis. [279] Cardiomyocytes have a negligible ability to regenerate and
during cellular damage or inadequate conditions, as seen in several cardiomyopathies,
excessive fibrosis will take place through either activation of fibroblast synthetic
pathways or a disproportionate matrix degradation. To further evaluate the effectiveness
of T3-Dex treatment and CTCM in modulating healthy structural adaptation in heart
slices, Masson’s Trichrome staining was performed on fixed heart slices to quantify
fibrosis interstitially. The location within the ventricle from which the slices are
harvested varies from one slice to another and the presence of capillaries and blood
vessels was common within the collected slices. To account for that, only interstitial
fibrosis was considered in the quantification and perivascular fibrosis was excluded, as
shown in Figure 4-9-A. Trichrome quantification revealed a significant reduction in
interstitial collagen in TD condition compared to CTRL, indicating the efficacy of T3Dex treatment in reducing fibrosis in pig heart slices, Figure 4-9-B. This is in congruous
with the anti-fibrotic effects of T3, likely due to inhibition of TGF-β1 dependent
pathways [280]. Interestingly, in the absence of T3-Dex treatment in CTCM culture (MC
condition) fibrosis was significantly reduced compared to CTRL condition. Importantly,
MT showed further reduction in area of fibrosis compared to MC. While MT condition
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did not completely stop the fibrotic remodeling, the combined effects of
electromechanical stimulation and T3-Dex small molecule treatment showed the best
reduction in the maladaptive fibrotic processes within the tissue.

Figure 4-9 A- Representative images obtained from Masson’s trichrome staining for all 4
conditions showing areas of interstitial fibrosis and perivascular fibrosis, B- Percentage
area fibrosis quantification as measured from Masson’s trichrome stained slices. N=10
per group. # groups compared to D0, # p<0.01. ***,**** groups compared to CTRL, ***
p<0.01, **** p<0.0001. $$, compared to MC, $$ p<0.01.
4.11 Transcriptional profiling of pig heart slices under electromechanical
stimulation and T3-Dex treatment
RNA sequencing was performed to evaluate the effects of electromechanical
stimulation and small molecules on the transcriptome, Figure 4-10. Heart slice tissue
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from all 4 conditions was collected at days 8, 10, and 12 and were subsequently
compared to fresh heart tissue from day 0. The goal of the transcriptional profiling was to
investigate the effects of physiological mechanical and humoral stimulation on heart
slices expression of cardiac and contractile genes. Compared to D0, unloaded conditions
(CTRL and TD) showed a significant downregulation of genes coding contractile protein
synthesis. Transcriptionally, the addition of T3-Dex treatment did not significantly
improve cardiac gene expression compared to CTRL. The introduction of
electromechanical stimulation in MC condition relatively improved expression of cardiac
and contractile genes compared to CTRL and TD but were still downregulated in
comparison to fresh tissue, as shown in Figure. 5. Interestingly, the combination of
electromechanical stimulation and T3-Dex treatment in MT condition resulted in an
expression profile most similar to fresh heart slices with only 30 differentially regulated
genes after 12 days in culture (23 genes downregulated and 7 genes upregulated).
Contractile filament protein coding genes (e.g., TNNT2, TNNC1, MYH7, and MYL3)
were all normally expressed compared to fresh tissue.
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Figure 4-10 Heat map showing log2-fold change in gene expression of representative
cardiac genes on days 8, 10, and 12 in culture compared with fresh heart slices (D0).

4.12 Modelling volume overload by the use of CTCM
Heart tissue is continuously exposed to external forces in-vivo and pathological
forces can induce diseased cardiac remodeling. The ability to model altered mechanical
environments is of particular importance for therapeutic and drug discovery. To illustrate
the ability of CTCM in modeling diseased mechanical states, the CTCM was used to
model volume overload condition was modeled. During volume overload, end-diastolic
volume is increased due to numerous abnormalities such as aortic and mitral valve
insufficiency. [281] The elevated ventricular preload causes increased stretching of the
cardiomyocyte beyond physiological levels and has been related to an array of
compensatory effects the most significant of which is eccentric hypertrophy. In eccentric
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hypertrophy, ventricular wall thickens due to increased fibrosis and myocardial fibrosis
while the ventricular lumen is dilated. In CTCM, the peak pressure in the air chamber
was increased from 80 mmHg (Normal stretch) to 140 mmHg, as shown in Figure 4-11.
This corresponds to a preload stretch of 32%. Heart slice tissue treated with T3-Dex
(MT) and without T3-Dex (MC) were either subjected to normal preload stretch (MCNorm, MT-Norm) or volume overload conditions (MC-OL,MC-OL) for 6 days. The heart
slices were assessed for viability, cardiomyocyte cell size, and fibrotic remodeling.

Figure 4-11 A- Percentage stretch during volume overload modeling assessed using a
custom camera system. The heart slices are stretched by 32% during diastole, compared
to 25% during normal physiological loading. B- Stretch rate during volume-overload
compared to normal physiological load. The peak contraction velocity is increased in
volume-overload compared to normal loading as well as the peak relaxation velocity.
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4.13 Hypertrophic and fibrotic remodeling with increased preload
stretch.
Pathological cardiac remodeling takes place in response to altered mechanical
states. The compensatory mechanisms which help adapt the heart to transient demanding
conditions (e.g., fight or flight and physical exercise). In contrast, pathological loading as
in valvular diseases, hypertension, or infarcted hearts will cause maladaptive remodeling.

Hypertrophic remodeling was assessed by staining the cell membrane using Wheat Germ
Agglutinin (WGA). Quantification of cardiomyocyte cross-sectional area revealed a
significant increase in cell size in both MC-OL and MT-OL compared to their respective
control (MC-Norm and MT-Norm), Figure 4-12. Further, to determine the formation of
fibrosis within the cardiac lattice, Masson’s trichrome was used. As shown in Figure
4-13, fibrosis was significantly increased in MC-OL and MT-OL compared to D0 and to
their respective controls. These results show clear evidence of pathological remodeling,
typical of volume overload conditions.
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Figure 4-12 WGA quantification of cardiomyocyte cell size in volume-overload
conditions MC-OL and MT-OL compared to normal physiological load and fresh heart
slices (D0). # Significant groups compared to D0, # p<0.01. * Significant groups
compared to MC-Norm, * p<0.05. $$$$, significant groups compared to MT-Norm, $$$$
p<0.0001. MT-OL showed a 7% increase in cell size compared to MT-Norm, while MCOL showed a 5% increase in cell size compared to MC-Norm. D0, N= 267. MC-Norm,
N= 346. MC-OL, N=294. MT-Norm, N =369. MT-OL, N=330.
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Figure 4-13 Fibrosis assessment using Masson’s trichrome staining after 6 days in
culture with volume-overload. A– representative images for trichrome staining from each
condition. B,C– %area fibrosis quantification asses for all conditions. #, significant from
D0, # p <0.01. **** significant from MC-Norm, **** p<0.0001. $$$$ significant from
MT-Norm, $$$$ p<0.0001. D0 , N= 18, MC-Norm, N =16, MT-Norm, N=16, MC-OL =
15, MT-OL, N=16. One-way ANOVA was used to determine significance.

4.14 Discussion
Translational cardiovascular research requires cellular models capable of faithfully
replicating the cardiac milieu. In this study, a cardiac tissue culture model (CTCM) that
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uses ultra-thin heart slices was developed and characterized. CTCM system encompasses
physiological synchronized electromechanical stimulation coupled with humoral
enrichment with T3 and Dex. Building on previous work by Ou et al. [120], these results
demonstrated improved viability, structural integrity, reduced fibrosis, normal energy
utilization for 12 days in culture. These results confirm the critical role of physiological
culture conditions in the maintenance of a normal cardiac phenotype.
Multiple factors contribute to the optimal environment for cardiomyocyte
functional survival. The most identifiable of these factors are related to 1) cell-to-cell
interactions through paracrine signaling as well as through force transduction, 2)
electromechanical stimulation, 3) humoral factors, and 4) metabolic substrates.
Physiological cell-to-cell interaction requires the presence of intricate 3-dimensional
multi-cell-type cellular networks with extra cellular matrix. While this factor is difficult
to recreate in-vitro, it lends itself easily in organotypic heart slices. Moreover, mechanical
loading of cardiomyocytes has been indicated to be of paramount importance in
preserving the cardiac phenotype. [282-284] While mechanical stimulation has been used
extensively in hiPSC-CM conditioning and maturation, few studies have attempted
mechanical loading of heart slices in culture. [121, 267] Indeed, these studies have shown
the positive influence of mechanical loading on the cardiac phenotype. However, the way
by which the heart slices were loaded did not replicate the physiological mechanical
loading by using either isometric stretch forces [267] or linear auxotonic loading [121]
and was reflected on the downregulation of multiple cardiac genes or the overexpression
genes related to pathological stretch response. Notably, Pitoulis et al. [262] developed a
dynamic heart slice culture bath to recreate the cardiac cycle using a force transducer
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feedback and a stretcher actuator. The main drawback with this system is complexity and
low throughput where the culture bath can only accommodate one heart slice at a time. In
the present platform, CTCM can provide electromechanical stimulation that mimics the
native cardiac cycle in terms of cycle timing and loading (25% preload stretch, 40%
systole, 60% diastole, and 72 beats per minutes). By replicating physiological strain
waveform (similar to the ventricular volume waveform), the mechanical loading of the
heart tissue can be modulated, which was demonstrated by simulating a volume-overload
condition.
T3 can influence transport of amino acids, sugars, and calcium across the cell
membrane as well as increase transcription of MHC-A, and decrease MHC-B. [285] The
lack of T3 in the normal heart, as with hypothyroid patients, can lead to loss of
myofibrillar striation, interstitial fibrosis, and reduced rate of tension development.[285]
On the other hand, Dex is mediated by the glucocorticoid receptor and has been shown to
increase cardiac contractility in ex-vivo perfused hearts [286] and this improvement is
thought to be related to an effect on store operated calcium entry (SOCE). [287, 288]
Interestingly, our results showed that physiological mechanical stimulation (MC)
improved overall culture performance compared to CTRL, but could not solely maintain
viability, structural integrity, and contractile protein expression after 12 days in culture.
The incorporation of T3-Dex treatment into CTCM culture resulted in improved viability
compared to transwell culture with electrical stimulation (CTRL), maintained 80%
structural similarity to fresh tissue, and provided most reduction in fibrosis formation
compared to all other experimental conditions. The effects of T3-Dex were also noticed
in the context of metabolic energy utilization where static heart slices treated with T3118

Dex (TD) showed normal glucose utilization for energy production compared to D0
which was also achieved in MC condition. Moreover, TD condition also showed
significant decrease in fibrosis and improvement in cx43 expression and structural
integrity compared to CTRL. This is consistent with previous studies indicating their
favorable effects on hiPSC-CM maturation, T-tubule development, and contraction. [289]
The current study shows 1) the beneficial effects of T3-Dex for cardiac maturation, in
line with past reports in previous studies using hiPSC-CMs, and 2) an interesting
synergistic effect of electromechanical and T3-Dex hormonal treatment on heart slice
functional integrity.
CTCM is considered a major advancement over the old transwell culture with
optimized media (CTRL), which was only able to maintain viability for 6 days in culture
and suffered severe downregulation of cardiac genes by day 10. [271] Here, CTCM
combination of electromechanical stimulation and T3-Dex treatment in MT condition
supported the hypothesis that biomimetic culture of myocardial slices can further
improve their survival and maintain their phenotype in culture and that a combination of
different physiological stimulants is needed to achieve that. Moreover, a single device
can accommodate up to 6 heart slices cultured under identical conditions. In our
experience, a single pneumatic driver can be connected up to 4 CTCM devices without
causing significant attenuation of the pressure due to membrane and tubing compliance.
Pathological volume-overload modeling using CTCM was achieved by controlling
the pulsatile pneumatic driver pressure, illustrating the versatility of the CTCM system.
Volume-overload culture showed typical effects associated with pathological
compensatory remodeling of the heart in MC and MT conditions where fibrotic processes
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and hypertrophic remodeling were both significantly increased by day 6 of culture. It
should be noted that CTCM parameters can be modulated to simulate many conditions
such as tachycardia, bradycardia, pressure overload, and mechanical circulatory support
(mechanically unloaded heart) by changing the pneumatic driver parameters. The
presented technology could be used to study cardiotoxic effects and efficacy of novel
therapeutic agents. Future studies will aim at including more in-depth assessments of the
CTCM cultured heart slices. Meaningful data should include continuous monitoring of
the contractile function of heart slices, and mechanical characteristics of heart slices over
days.

4.15 Limitations
In this study, ultra-thin heart slices were prepared from pig heart slices. CTCM
culture using porcine heart tissue showed preserved viability, physiological energy
utilization, similar structure to fresh heart tissue, and normal expression of contractile
proteins. However, the study lacked confirmation of these findings using tissue of human
origins. Further, the mechanical loading of the slices within the culture in CTCM was
applied by stretching the tissue in a controlled manner within physiological limits and
hence loading the tissue while it actively contracts. In CTCM. While our results show
normalized contractile gene expression, improved cardiac structure, z-disc alignment and
gap junction cx43, CTCM does not allow for active monitoring of cardiac contraction
during each cycle. The size of tissue that can be used with this device was limited to only
7mm diameter. This limitation is to make sure that tear-free circular slice can be
extracted from the tissue. Lastly, the CTCM is of medium complication and includes
multiple parts that need to be assembled together including pressurized air from a
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pulsatile pneumatic driver which needs to be connected into an incubator and provides a
possible source of contamination.

4.16 Conclusion
A novel cardiac tissue culture model was developed that allows for maintained
culture of adult myocardial slices under physiological mechanical and humoral
stimulation. The study showed that the addition of T3-Dex hormonal treatment
significantly improved heart slice culture viability, structural integrity, and energy
utilization. CTCM demonstrated the ability to model pathological conditions, which can
be used to test drugs and therapies. The cardiac milieu is complex and the ability to
replicate some of its constituents showed that it can improve heart slice culture in-vitro.
This study provides a major advancement over current methodologies, including the
ability to mimic the cardiac cycle while maintaining adequate throughput, providing
synchronized electromechanical stimulation, and combining humoral stimulation (T3Dex) with optimized media rich with nutrients.

4.17 Methods
Heart tissue collection from pigs
To collect heart tissue from pigs, all animal procedures were in accordance with
institutional guidelines of the University of Louisville and approved from the Institutional
Animal Care and Use Committee (IACUC). Pig hearts are clamped at the aortic arch and
subsequently perfused with 1L sterile cardioplegia solution (110 mM NaCl, 1.2 mM
CaCl2, 16 mM KCl, 10 mM , 6 mM MgCl2, NaHCO3, 5 U/mL heparin, and set to a pH of
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7.4). The hearts were preserved in ice-cold cardioplegia solution and transported to the
lab.
Heart slicing
As described in detail here [271], pig hearts are packaged in sterile glass container
with cardioplegia solution containers. The left ventricle is sectioned into 1-2 cm3 blocks.
Epicardial side of the block was glued onto 4% agar bed using histoacryl glue and
subsequently glued on top of the specimen holder of the Vibrating Microtome 700SMZ
(Campden Instruments). The cutting bed was filled with 4°C modified Tyrode’s solution
(Tyrode’s solution (140 mM NaCl, 6 mM KCl, 10 mM glucose, 10 mM HEPES, 1mM
MgCl2, 1.8 mM CaCl2) and 2,3-butanedione monoxide (BDM) 10mM and set to pH 7.4.
To limit cardiomyocyte damage while slicing, the vibrating microtome’s z-axis vibration
was calibrated with the ceramic cutting blade to <0.5 µm. The vibrating microtome was
set to produce 300 um thick slices with an advance speed 0.03 mm/s and 80 Hz vibration
frequency and 2mm horizontal vibration amplitude. The heart slices were the immersed
in Tyrode’s solution without BDM in a cold bath for at least 20°C to wash out BDM
before being glued to the ring supports.
Heart slice culture
Transwell culture:
The same protocol previously described by Ou et al. [120] was used. Here, heart
slices were glued at their edges using histoacryl glue to polyurethane supports (6 mm
width). The supported slices were transferred into 6 well plates containing 6 mL of
stimulated medium. The composition of the medium is Medium 199, 1x ITS supplement,
10% FBS, 5 ng/mL VEGF, 10 ng/mL FGF-basic, and 2X Antibiotic-Antimycotic). The
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C-Dish top (IonOptix, Westwood, MA) with 6 pairs of graphite electrodes were placed
on top of the 6 well plate and connected to the C-Pace-EM system (IonOptix, Westwood,
MA) and stimulated at 10V and 1.2 Hz. The plates were placed in the incubator at 37 C
with humidified air and 5% CO2. C-Dish top was swapped every day to avoid build up of
contaminants on the electrodes. Culture media was changed 3 times a day and either
supplemented with T3-Dex (100 nM T3, and 1 µM Dex) with every media change.
CTCM culture:
Heart slices were first placed on a custom 3D-printed apparatus to oversize the
heart slices by 25% of the support ring area. The apparatus was placed in a modified
Tyrode’s solution bath to ensure complete contractile filament decoupling. The oversize
apparatus ensures the heart slices are not over-stretched when they are taken out of the
Tyrode’s solution and placed in media. The ring support were prepared with histoacryl
glue and push against the tissue as shown in Figure 4-14. The ring supports with sealing
O-rings were placed in the CTCM device prefilled with 21 mL of stimulated media
(Medium 199, 1x ITS supplement, 10% FBS, 5 ng/mL VEGF, 10 ng/mL FGF-basic, and
2X Antibiotic-Antimycotic). The process was repeated for each ring and finally the cover
plate with graphite electrode pairs and custom interface C-PACE-EM system was placed
on top and set to provide 4 V at 1.2 Hz, 2ms biphasic stimulation. The assembled device
was then placed in temperature and humidity-controlled incubator, 37°C with humidified
air and 5% CO2. The pneumatic driver was then turned on and the air flow valve was
turned on. Media was changed twice every day, and the graphite electrodes were
swapped every day to avoid buildup of contaminants within the electrode pores. T3-Dex
treatment was added with every media change at 100 nM T3, and 1 µM Dex.
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Figure 4-14 3D-printed oversizing apparatus to ensure no mechanical stretch on the
unloaded heart slice once glued on the ring. The load-free heart slice in Tyrode’s solution
with BDM is oversized 25% by area compared to the ring area.
CTCM fabrication, design, and dimensions
Culture chamber, air chamber, support rings, silicone membrane, and gaskets:
CTCM was designed in SolidWorks Computer Aided Design (CAD) software.
Parts were CNC machined out of clear acrylic plastic. Support rings were center-lathed
from high density poly-ethylene plastic (HDPE). The support ring is equipped with an Oring groove that accommodate a silicone O-ring for sealing the media volume below the
ring. The silicone membrane was laser-cut out of 0.02’’ silicone sheet, durometer 35A.
The bottom and top silicone gaskets were laser-cut from 1/16’’ silicone sheet, durometer
50A. 316L stainless steel screws and wing nuts were used to sandwich the body parts
together to create an air-tight seal. Gross part dimensions are shown in Figure 4-15.
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Figure 4-15 Technical drawings of CTCM parts. A- HDPE support ring with O-ring
groove, B- Culture chamber, C- Air chamber, and D- middle plate.
Electrical connections and device cover:
A custom PCB was designed to integrate with the C-PACE-EM system and is shown in
the figure below. Swiss machine headers outlets on the PCB are each connected to a
graphite electrode via silver plated copper wires and 0-60 bronze screws that are
threaded into the electrodes. The PCB fits into a 3D printed device cover. Cover
dimensions and schematic of the electrode interface is shown in Figure 4-16.
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Figure 4-16 A- Custom interface PCB with C-PACE-EM system, B- 3D printed cover
with sockets for 6 electrodes for electrically stimulating heart slices.

Heart slice movement assessment using MUSCLEMOTION
To obtain a movement trace of the heart slices, a custom camera system was
developed. A DSLR camera (Cannon Rebel T7i, Cannon, Tokyo, Japan) was used with a
Navitar Zoom 7000 18-108mm Macro Lens, (Navitar, San Francisco, CA). The camera
was placed at a 51° angle and videos were recorded at 30 fps. First a mask was created
using MATLAB (MathWorks, Natick, MA, USA) to define the region of interest which
is the beating heart slice to avoid any noise from extraneous effects. The manually
segmented mask was applied to all images in the frame sequence and then fed to the
MUSCLEMOTION plugin. Briefly, MUSCLE motion uses the average pixel intensity
within each frame to quantify its movement relative to a reference frame. The contraction
data was recorded, filtered, and used to quantify the cycle time and assess the tissue
movement. The process is shown in Figure 4-17.
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Post processing of recorded videos was performed using a zero phase first order
digital filter. To quantify the tissue movement (peak to peak), peak analysis was
performed to distinguish the peaks and valleys of the recorded signal. Additionally,
detrending was performed to remove signal drift using a 6th order polynomial. Software
code was developed in MATLAB to detect overall tissue movement, cycle time,
relaxation time, and contraction time.

Figure 4-17 Assessment of heart slice movement in CTCM using MUSCLEMOTION
with Image-J. Each frame was segmented and stacked. The stack was used to calculate
the contraction data.
Quantification of tissue stretch during the cycle
To calculate the peak movement of the heart slices, frame-by-frame analysis was
performed manually using Image J, (NIH, Washington DC, USA). The center point of the
tissue was tracked manually at each frame and a peak trace was calculated with the aid of
a reference length (the ring diameter, 7mm) and the camera incline. Pixel length
measurements were converted using the following equation

𝑆=

𝐿𝑚 [𝑝𝑖𝑥𝑒𝑙𝑠]
× 7 [𝑚𝑚]
𝐿𝑟𝑒𝑓 [𝑝𝑖𝑥𝑒𝑙𝑠] × cos(∅)
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(13)

Where 𝑆 is the tissue peak movement in mm, 𝐿𝑚 is the measured peak movement in
pixels, 𝐿𝑟𝑒𝑓 is the ring diameter as in the frame in pixels, and ∅ is the camera inclination
angle in degrees. Tissue movement was approximated a membrane movement that
follows the equation [290]
𝑟 2 2
𝑦(𝑟) = 𝑆 (1 − ( ) )
𝑅

(14)

Where 𝑦 is the upwards deflection of the tissue at distance 𝑟 from the center, 𝑆 is the
tissue peak movement at any frame, 𝑟 is the distance from the center, and 𝑅 is the tissue
diameter.
Once the peak movement was determined at each frame, %area stretch was calculated
using surface rotation of equation 14

𝑅

%𝑠𝑡𝑟𝑒𝑡𝑐ℎ = (𝜋𝑅 − ∫ 2𝜋𝑟√1 + (
2

0

𝑑𝑦 2
) 𝑑𝑟)/𝜋𝑅 2 × 100
𝑑𝑟

(15)

These calculations were performed using custom software written in MATLAB.
FEA to determine Electric field distribution in the culture chamber
ANSYS Workbench software was used to model and simulate the electrical field
potential and electrical voltage within the culture chamber. Adaptive meshing optimized
for electrical simulation was used and resulted in 10171 elements. The voltages at each
electrode were used as inputs (4.0 V for positive, and 0 V for ground).
FEA to determine the strain field within the heart slice
Ansys Mechanical was used to simulate the strain field within the heart slices
with SOLID 187 elements. Adaptive meshing was used and resulted in 2956 elements.
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The circular tissue was modeled in 3-D with fixed support boundary conditions on the
outer edge of the tissue. The peak central movement recorded with the camera system
was used as reference for the FEA. To model the maximum strain on the tissue (end of
diastole), the maximum center deflection was used which was calculated as 2.1 mm.
Pressure was applied to the bottom of the tissue model equally. Large deflection setting
was turned on to account for non-linear effects.
Immunohistochemical staining
Heart slice fixation, mounting and immunofluorescence:
Heart slices were fixed in 4% paraformaldehyde for 24 hours. Fixed tissue
underwent dehydration in 30% sucrose overnight and was then embedded in optimal
cutting temperature compound (OCT compound) and gradually frozen in isopentane/dry
ice bath. OCT embedded blocks were stored at -80°C until sectioning. 8μm crosssectional sections were cut and immune-stained for target proteins.
Immunofluorescent staining:
To remove the OCT, compound the slides were heated for 5 minutes at 95°C until
the OCT compound melted. 1-2 ml of PBS were added to each slide and incubated at
room temperature for 10-30 minutes until the OCT compound washed off. Sections were
then permeabilized by incubating them for 30 minutes with 0.1% Triton-X in PBS at
room temperature. Triton-X was washed with PBS and non-specific antibody binding in
the sections was blocked by 3% BSA solution for 1 hour at room temperature. After
washing BSA with PBS, the primary antibodies (1:100 dilution in 1% BSA) (Connexin
43 (Abcam; #AB11370), and Troponin-T (Thermo Scientific; #MA5-12960), were added
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to the section for 90 minutes followed by the secondary antibodies (1:200 dilution in 1%
BSA) Anti-mouse Alexa Fluor 488 (Thermo Scientific; #A16079), Anti-rabbit Alexa
Fluor 594 (Thermo Scientific; #T6391) for another 90 minutes separated by 3 washes
with PBS. To distinguish the target staining from background, we used a secondary
antibody only as a control. Finally, the DAPI stain was added, and the slides were
mounted in vectashield (Vector Laboratories) and sealed with nail polish. For WGA
staining, WGA-Alexa Fluor 555 (Thermo Scientific; #W32464) was used at 5 µg/mL in
PBS and was applied to fixed sections for 10 minutes at room temperature, followed by
wash and addition of mounting media and nail polish sealant. All immunofluorescence
imaging and quantification was performed using a Cytation 1 high content imager and the
fluorescent signal quantification and masking was performed using the Gen5 software
Trichrome staining
Fixed slides were first heated for 10 minutes at 95 C to melt OCT. PBS was added
to each slide to remove any remaining OCT for 30 minutes. Slides were submersed in
Bouin’s solution (Picric acid, Formaldehyde, and glacial acetic acid) overnight (12 hours)
to improve the staining quality. The slides were then rinsed with running tap water for 15
minutes to remove Bouin’s solution yellow color. The slides were then stained in
Biebrich scarlet acid fuchsin (1% aqueous, 1% aqueous, and glacial acetic acid) solution
for 10 minutes and then washed running DI water. The slides were then differentiated in
phosphomolybdic-phosphotungstic acid solution (5%-5%) for another 10 minutes to
remove red color from collagen. Without rinsing, the slides are directly transferred into
aniline blue solution to stain for 10 minutes. Then the slides were rinsed again with DI
water and differentiated in 1% acetic acid solution for 2 minutes. After rinsing with
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running DI water, the slides were dried in 200 proof ethyl alcohol and subsequently
transferred into xylene to clear off Biebrich scarlet-acid fuchsin staining. Mounting media
is then added, and coverslips are sealed on with nail polish.
MTT assay
CyQUANT™ MTT Cell Viability Assay (Invitrogen, Carlsbad, CA), catalogue #
V13154 was used according to the manufacturer’s protocol with some modifications.
Briefly, a 6 mm surgical punch was to collect heart slice tissue to perform the MTT assay
and ensure similar tissue weights were used. The punches were each placed in a well of
12 well plate containing 0.9 ml of growth media with 0.1 ml of the reconstituted MTT
substrate according to the manufacturer’s protocol. The tissues were incubated for 3
hours at 37°C and viable tissue metabolized the MTT substrate creating a purple color
formazan compound. To extract the purple formazan from the heart slices, The growth
medium was removed and 1 ml of DMSO was added to each tissue and incubated it at
37°C for 15 minutes, or until the tissue was translucent and no longer dark purple.
Samples were diluted 1:10 in DMSO and the intensity of the purple color was measured
using a Cytation plate reader (BioTek) at 570nm using a 96 well plate reader. The
readings were normalized to the weight of each heart slice and converted into OD/mg
tissue.
Statistical Analysis
Prism software (GraphPad, San Diego, CA) was used to perform all statistical
analysis. One way ANOVA was used to determine significance between multiple groups
with p-value cut off at 0.05 confidence interval. Kolmogorov–Smirnov test for normality

131

was first used to determine if parametric or non-parametric tests were warranted. To
compare between individual groups, Tukey HSD post hoc test was used.
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CHAPTER 5: CONCLUSION
5
5.1 Summary
Cardiovascular diseases are responsible for the most mortality globally and in the
United States. The ability to model different elements of the cardiovascular systems at
different degrees of complexity offers great power in the search for appropriate treatment
for cardiovascular diseases. In-silico simulations are gaining attention because of their
ability to model many biological phenomena at a low cost. Cellular and tissue level
models provide an adequate platform for basic science discovery as well as drug testing
due to their versatility and high throughput. However, limitations for cell and tissue
culture systems are clear when extraneous stimulants become relevant in the context of
the desired experimental model. The complexity of the cardiovascular system exacerbates
this limitation due to the presence of multiple factors that come into the regulation and
maintenance of the normal homeostasis. (e.g., hemodynamic loading, neuro-hormonal
factors, downstream feedback mechanisms, metabolic substrate, cell-cell interaction …,
etc.). Unfortunately, this has resulted in cell and tissue-level studies with little
physiological relevance.
In this dissertation, three models encompassing different components of the
cardiovascular system at different degrees of complexity were used/ developed in their
relevant application.
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Firstly, an extensive lumped parameter model of the cardiovascular system was used to
model the hemodynamics of blood flow. This in-silico model was used to help solve on
the lingering problems with chronic mechanical circulatory support; that is physiological
control of CFLVADs. A novel sensorless control algorithm was developed and tested
using this model. Using the pump speed pulsatility the control algorithm was able to 1)
Adjust pump flow to tissue demand, 2) avoid ventricular suction by over pumping, and 3)
augment arterial pulsatility through the incorporation of a pulsatile mode. The sensorless
algorithm avoids the use of implantable pressure or volume sensors that can drift or the
use of unreliable model-based estimations. The use of computer simulation to develop
this algorithm greatly sped up its optimization, which would have otherwise been time
consuming.
The second problem addressed in this work was the choice of appropriate
pulsatility augmentation strategy that can mitigate vascular adverse events caused by
diminished pulsatility in CFLVAD flow. To address this, a microfluidic endothelial cellsmooth muscle cell model was developed to model the arterial vascular wall and simulate
the hemodynamic loading it is subjected to. The results showed that pulse frequency and
pulse magnitude are both relevant variables to the normalization of endothelial cells and
smooth muscle cells morphology and that in the absence of stretch the effects of flow
hemodynamics on cell morphology may only be communicated to smooth muscle cells
through endothelial paracrine secretion. This model may be further used to identify
relevant biomarkers to optimize the pulse flow modulation strategy.
Lastly, a cardiac tissue culture model that utilizes thin heart slices was developed.
CTCM is a platform technology that provides a medium throughput system that can
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replicate the electromechanical environment within the heart. The study with CTCM
showed that humoral stimulation in the form of T3 and dexamethasone can further
enhance the viability and structural integrity of heart slices in culture. The
characterization and conceptual proof were demonstrated using CTCM and its ability to
replicate diseased state was exemplified. The system can be used for drug discovery and
study of various conditions associated with cardiovascular diseases.
In the context of CFLVAD, CTCM system can be used to test the effects of
mechanical unloading on the heart muscles. It is well known that CFLVAD support can
cause cardiac atrophy. Hence, pulse flow modulation strategies, in addition to
augmenting arterial pulsatility, can be used to intermittently load and unload the native
ventricle.

5.2 Future work
Pulsatility-based ΔRPM control:
In-silico simulations using a lumped parameter model showed the feasibility of this
type of physiological control. Noting that there are no physiological control algorithms
that are FDA-approved to date, further validation of this algorithm must be performed invitro using mock flow loop on physical pumps followed by animal studies.
Studying pulse flow modulation in EC-SMC coculture model:
The study conducted using EC-SMC coculture was restricted to the
characterization of the system and the flow regime, stretch, and pressure within the
culture chamber analytically and using CFD. Effects on ECs and SMCs were limited to
morphological changes. In future work, it is necessary to interrogate the system by
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investigating relevant biomarkers related to inflammatory response, oxidative stress,
contractile protein expression, and paracrine signaling as well as full transcriptional
profiling. This way the most relevant biomarkers can be narrowed down, studied, and
used to optimize modulation strategies. Beyond pulse flow modulation assessment, ECSMC coculture model provides an excellent tool to study tissue response to drug
therapies in a physiologically relevant platform.
Electromechanical stimulation of heart slice tissue:
Future work using CTCM must include the use of human heart slices to confirm the
study findings from pig heart slices. In the study, the CTCM system was extensively
characterized by the assessment of cellular targets. In addition, the mechanical loading of
the heart slices in terms of physiological strains. However, a major improvement to the
system would be the addition of continuous monitoring of the active contraction of the
individual heart slices. Further, quantification of changes in heart tissue stiffness is a
good indicator of its composition and may provide a good and easy way to assess
remodeling progression temporally.
Lastly, this system can be used extensively to study different pathological
conditions. Molecular and cellular studies of myocardial slices can be investigated under
these pathological conditions.
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